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CHAPTER I 
 
INTRODUCTION 
 
Biology and Biochemistry of COX enzymes 
 
Prostaglandins. Prostaglandins are important signaling molecules that mediate a diverse 
array of physiological and pathophysiological events throughout the body. The synthesis 
of these bioactive lipids is regulated by three distinct enzymatic reactions (Figure 1). 
First, upon activation, phospholipase A2 (cytosolic or secretory) can release arachidonic 
acid (AA) from the phospholipid bilayer, which allows AA to then bind in the active site 
of cyclooxygenase (COX) enzymes. COX, also known as prostaglandin endoperoxide H 
synthase, catalyzes the conversion of AA to prostaglandin H2 (PGH2). Finally, tissue 
specific synthase enzymes convert PGH2 to the prostaglandins (PGE2, PGD2, PGF2α), 
prostacyclin (PGI2) and thromboxane (TXA2) (1).  Prostanoids then exert their effects by 
signaling through separate G-protein coupled receptors (GPCRs) (2).  
As mentioned above, prostaglandin signaling is involved in a variety of biological 
functions. For example, prostanoids play a major role in the maintenance of vascular 
homeostasis. Vascular endothelium-derived PGI2, a vasodilator and anti-thrombotic 
agent, are thought to counterbalance the effects of TXA2, which induces vasoconstriction 
and thrombosis (3-6). PGE2 and PGI2 are also important regulators of kidney function and 
gastric cytoprotection (7,8). Pathophysiological responses mediated by prostanoid 
signaling include pain, fever, inflammation, and tumorigenesis (4,9,10), reviewed in 
(11,12).    
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Figure 1.  Biosynthesis of prostanoids. 
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            COX, which catalyzes the committed step in prostaglandin biosynthesis, was first 
characterized in 1967 from preparations of sheep vesicular gland (13). COX enzymes are 
membrane-bound homodimers localized to the lumen of the endoplasmic reticulum and 
the inner and outer membranes of the nuclear envelope (14). One molecule of heme 
(Fe3+-protoporphyrin IX) is non-covalently associated with each 70 kDa COX monomer. 
The heme moiety is required for catalysis but can be removed and reconstituted with 
minimal effects on enzyme activity (15,16).  
 
The COX reaction. The conversion of AA to the parental prostaglandin, PGH2, occurs at 
two spatially distinct but functionally coupled active sites within the COX enzymes. The 
bis-dioxygenation of AA takes place in the L-shaped cavity of the COX active site, 
resulting in the formation of the hydroperoxy endoperoxide, prostaglandin G2 (PGG2) 
(17). PGG2 then diffuses out of the COX site to the peroxidase (POX) active site, where it 
undergoes a rapid two-electron reduction to form the hydroxy endoperoxide, PGH2 (18). 
Hydroperoxides other than PGG2 can be reduced in the POX active site, and initiation of 
the COX reaction is dependent upon a two-electron oxidation of the heme moiety at the 
POX site. The necessity for heme oxidation at the POX active site to initiate COX 
catalysis is best explained by a branched-chain mechanism as shown in Figure 2 (19). 
The two-electron oxidation of heme occurs in conjunction with the two-electron 
reduction of a hydroperoxide substrate, and results in the formation of a ferryloxo 
protoporphyrin radical cation ((PPIX•)+Fe4+O) termed Compound I (20,21).  In the 
presence of a reducing co-substrate, two subsequent one-electron reductions return the 
heme moiety to its resting state (22) (23). Alternatively, Compound I can abstract a 
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hydrogen from Tyr-385 in the COX active site leading to the formation of a tyrosyl 
radical, thereby initiating the oxygenase reaction. 
 Hamberg and Samuelsson first proposed that COX catalysis was mediated by a 
free radical mechanism in 1967 (13,24,25). Their hypothesis was later supported by 
electron spin resonance spin-trapping experiments to detect carbon-centered radicals, and 
is the basis for the putative mechanism of the COX reaction described herein (26). When 
a fatty acid substrate, namely AA, is bound within the COX active site, the tyrosyl radical 
at position 385 can abstract the 13-pro-(S) hydrogen forming a carbon-centered 
arachidonyl radical. As shown in Figure 2, this radical is trapped at C11 by molecular 
oxygen producing an 11-(R)-peroxyl radical, which undergoes two subsequent 
cyclizations to form a bicyclic endoperoxide and an allylic radical with electron density 
at C13 and C15. A second molecule of molecular oxygen traps the radical at C15, and 
reduction of this newly formed peroxyl radical by Tyr-385 generates PGG2. This final 
step also serves to regenerate the tyrosyl radical, which allows for additional rounds of 
COX catalysis independent of POX activity. In addition to prostaglandins, the COX 
enzymes produce a variety of minor products. For example, 11-
hydroperoxyeicosatetraenoic acid (11-HpETE) is formed if the 11-(R)-peroxyl radical 
does not undergo cyclization to form the endoperoxide ring at C9, while 15- 
hydroperoxyeicosatetraenoic acid (15-HpETE) is formed when molecular oxygen traps 
the initial arachidonyl radical at C15 rather than C11.  
The number of turnovers of each COX molecule is limited by reaction-catalyzed 
self-inactivation of the COX enzymes in vitro; this is a first-order, irreversible process. 
The precise mechanism of auto-inactivation remains unclear, but there is evidence for the 
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loss of both POX and COX activities. Furthermore, the self-inactivation of both activities 
appears to be hydroperoxide-dependent, but the concentration and structure of the 
hydroperoxide involved does not significantly affect the rate of inactivation (27).  It has 
been hypothesized that active radical intermediates, formed after the radical is transferred 
from Compound I to Tyr-385, react with the protein leading to modification of the heme 
or protein and loss of activity. It appears that the oxoferryl heme, rather than the tyrosyl 
radical, is the source of the damaging species (28). Interestingly, various reducing co-
substrates protect COX enzymes from self-inactivation (29). The physiological relevance 
of COX suicide inactivation is unknown, as in vitro reaction conditions do not exactly 
mimic the cellular environment of the enzyme. However, it has been shown that low 
levels of fatty acid hydroperoxides irreversibly inactivate COX derived from intact 
platelets (30,31). Additionally, in intact vascular tissue, there is evidence that AA 
metabolism, and subsequent hydroperoxide generation, leads to self-catalyzed COX 
inactivation; this is thought to be the limiting factor in endothelial PGI2 biosynthesis (32). 
Therefore, the self-inactivation of COX may act as a mechanism of autoregulation in 
vivo. 
 
Two COX isoforms.  The mechanistic studies described above were largely performed 
with COX-1, which was first purified from bull seminal vesicles in 1976 (15). A second 
COX isoform, dubbed COX-2, was discovered in the early 1990’s and found to share 
approximately 60% sequence identity with COX-1 (33). The mechanism of catalysis is 
fundamentally the same for COX-1 and COX-2, but there are key structural and 
functional differences between the two isoforms. The COX-1 gene, Ptgs-1, is 
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Figure 2.  Branched chain mechanism for COX catalysis. In the POX active site, the 
heme moiety, (PPIX)Fe3+, undergoes a two-electron oxidation to form Compound I, 
(PPIX•)Fe4+O, while the hydroperoxide substrate (ROOH) undergoes a two-electron 
reduction. The enzyme can be brought back to its resting state by two subsequent one-
electron reductions or the radical can be transferred to a tyrosine residue in the COX 
active site. When AA is bound within the COX active site, the newly formed tyrosyl 
radical can abstract the 13-pro-(S) hydrogen from the fatty acid substrate. AA undergoes 
several radical rearrangements in addition to two oxygenation reactions to allow the 
formation of the hydroperoxy endoperoxide, PGG2. The radical is then transferred back to 
the tyrosine residue to allow the initiation of subsequent catalytic cycles.  
Compound I 
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constitutively transcribed throughout the body and codes for a relatively stable 2.8 kb 
mRNA. While Ptgs-2, which codes for COX-2, is an immediate early gene that is 
activated by various stimuli including cytokines, growth factors, and tumor promoters. 
An instability sequence in the 3’-untranslated region leads to the rapid turnover of the 4 
kb COX-2 mRNA. 
 The constitutive expression of COX-1 suggests that this isoform is primarily 
involved in the immediate release of prostaglandins following activation of 
phospholipase A2 as occurs with platelet aggregation, and in “ housekeeping functions” 
such as cytoprotection in the stomach, whereas the inducible expression of COX-2 
indicates a role for this isoform in the formation of prostaglandins in pathophysiological 
states, namely pain and inflammation.  However, this paradigm is oversimplified as 
COX-2 is constitutively expressed in the kidney, cardiovascular system, and specific 
regions of the central nervous system, and COX-1 is reportedly induced in 
neuroinflammation and cellular differentiation.  
 “Knock-in” studies, in which Ptgs-1 is inserted under the regulatory sequence that 
controls Ptgs-2 expression in mice, indicate that the two COX isoforms are not 
functionally interchangeable (34). In macrophages from knock-in mice, COX-1 is 
expressed in response to stimuli that induce COX-2 expression, but the enzyme fails to 
produce PGE2 at low concentrations of AA. Analysis of urinary prostaglandin metabolite 
profiles revealed that COX-1 knock-in can effectively restore PGE2 levels, which are 
markedly reduced in COX-2 null mice, but only partially compensates for the decrease in 
PGI2 biosynthesis. COX-2 deletion also results in significant defects in reproductive and 
renal function, which are only partially rescued or delayed in COX-1 knock-in mice.  
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The inability of COX-1 to completely compensate for COX-2 in vivo may be 
related to differences in sensitivity to hydroperoxide activation, as the concentration of 
hydroperoxide required to activate COX-2 is approximately one order of magnitude 
lower than the hydroperoxide concentration necessary for COX-1 activation in vitro (35). 
These findings suggest that COX-2 may be able to function in cells with low 
hydroperoxide or substrate concentrations, while COX-1 remains inactive. The basis for 
the differential hydroperoxide requirement is unknown, but appears to be related to the 
identity of the side chain at position 383 as mutation of Thr-383 in COX-2 to the 
corresponding COX-1 residue, histidine, leads to a reduction in COX activation 
efficiency (36). Selective coupling of COX-1 and COX-2 with specific downstream 
synthase enzymes may also play a role in the differences in isoform function observed in 
the knock-in studies (37).  
 COX-1 and COX-2 also exhibit differences in protein turnover. In both murine 
NIH/3T3 fibroblasts and HEK293 cells, COX-2 is preferentially and rapidly degraded 
under conditions in which COX-1 is quite stable (38). Interestingly, degradation of COX-
2 is slowed by the addition of proteosome inhibitors. This is in agreement with studies 
indicating that, in addition to degradation associated with suicide inactivation, COX-2 is 
a target of the ER-associated degradation (ERAD) pathway, a quality control system in 
which N-glycosylated proteins residing in the ER lumen are transported across the ER 
membrane and subsequently ubiquitinated, then degraded by the 26 S proteosome. COX-
2 contains an additional 19 amino acids at the C-terminus (594-612) that are not present 
in COX-1, and there is evidence that this region of the enzyme is responsible for targeting 
COX-2 to the ERAD system (38). Three N-glycosylation sites are conserved between the 
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two COX isoforms, but the cassette of 19 amino acids unique to COX-2 contains a fourth 
N-glycosylation site, Asn-594. Mutation of Asn-594 stabilizes COX-2, suggesting that 
glycosylation of this residue is critical for entry into the ERAD pathway. 
 
COX Enzymes and the Endocannabinoid System 
 
Endocannabinoid biochemistry and physiology. A critical difference between COX-1 and 
COX-2 lies in their ability to oxygenate neutral derivatives of AA, particularly the 
endocannabinoids arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). 
Endocannabinoids target the same GPCRs that are engaged by the active component of 
marijuana (Cannabis), Δ9-tetrahydrocannabinol. To date, two cannabinoid receptors have 
been identified, termed CB1 and CB2  (39,40). AEA is a partial agonist of CB1, whereas 
2-AG is full agonist at the CB1 and CB2 receptors. CB1 is expressed throughout the 
central nervous system with the highest expression in the basal ganglia, hippocampus, 
and cerebellum, whereas CB2 is predominantly expressed in the immune system (41) 
(40). Both CB1 and CB2 can modulate adenylate cyclase and mitogen-activated protein 
kinase activity, but CB1 appears to couple to ion channels while CB2 does not. 
Cannabinoid signaling is thought to play a role in a variety of biological processes 
including cognition, motor function, food intake, body temperature, pain, and 
inflammation. 
AEA was identified in 1992 through a screen for endogenous ligands for 
cannabinoid receptors (42). The synthesis of AEA is a two-step process. First, N-
acyltransferase catalyzes the transfer of AA from phosphatidylcholine to the head group 
of phosphatidylethanolamine leading to the formation of N-arachidonoyl 
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phosphatidylethanolamine (NAPE). AEA can then be generated upon cleaveage of 
NAPE, which can occur through three distinct enzymatic pathways: hydrolysis of NAPE 
by a NAPE-selective phospholipase D, deacylation of NAPE by α/β hydrolase 4 and 
subsequent cleavage of the glycerophosphate, or phospholipase C-mediated hydrolysis of 
NAPE to generate phosphoanadamide, which can then be dephosphorylated (43,44).  
2-AG was identified and isolated from mammalian intestinal tissue in 1995 
(45,46). The concentration of 2-AG in the brain is 170 times greater than that of 
anadamide (47), but like AEA, multiple pathways may lead to the generation of 2-AG. 
The best-characterized pathway begins with the hydrolysis of AA-containing 
phosphatidylinositol-4,5-bisphosphate by phospholipase C-β to form the corresponding 
1-acyl-2-arachidonoyl-diacylglycerol (DAG) (44). This intermediate is then hydrolyzed 
by DAG lipase to generate 2-AG.  
Termination of endocannabinoid signaling can occur via hydrolysis by serine 
hydrolases or oxidative metabolism by COX, lipoxygenase (LOX), or cytochrome P450 
(CYP) enzymes. Fatty acid amide hydrolase (FAAH) hydrolyzes AEA to form AA and 
ethanolamine. Although not specific for AEA, FAAH appears to tightly regulate its 
levels. FAAH can also mediate 2-AG hydrolysis, but the major metabolizing enzyme for 
2-AG has been identified as monacylglycerol lipase (MAGL), which metabolizes 2-AG 
to yield AA and glycerol. Cravatt and colleagues developed a selective inhibitor of 
MAGL, dubbed JZL-184, and investigated its ability to block 2-AG hydrolysis in vivo 
(48). In mice, administration of JZL-184 led to an 8-10 fold increase in 2-AG levels and a 
broad array of cannabinoid behavioral effects, including analgesia, hypothermia, and 
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hypomotility. These studies suggest that inhibitors of MAGL, and possibly FAAH, can 
be useful probes in the examination of the endocannabinoid sysem (48). 
 
COX-dependent endocannabinoid oxygenation. As mentioned above, endocannabinoids 
also serve as substrates for oxygenase enzymes. Of particular interest to this work is the 
oxygenation of endocannabinoids by the COX enzymes (Figure 3). Yu et al. reported the 
first evidence of COX-mediated endocannabinoid metabolism in 1997 (49).  In their 
studies, partially purified hCOX-2, but not hCOX-1, metabolized AEA at rates 
approaching those observed with AA. Further analysis utilizing lysates and intact cells 
confirmed the selective metabolism of AEA, as only those cells or extracts expressing 
COX-2 were able to oxygenate the endocannabinoid. In contrast with initial reports, 
kinetic evaluation of COX-2-mediated AEA metabolism indicated that, to the extent that 
Km reflects Kd, the enzyme had a significantly lower affinity for AEA than AA (Km > 60 
µM for AEA versus approximately 10 µM for AA) (50,51). The products of AEA 
oxygenation by COX-2 parallel those of AA with the major products being PGH2-
ethanolamide (PGH2-EA) and to a lesser extent HETE-ethanolamides (HETE-EA). It 
remains to be seen whether or not this reaction is physiologically relevant as the low 
concentrations of AEA found in vivo, combined with the limited activity of COX-2 
against the endocannabinoid, may impede product formation.   
Similar to AEA, 2-AG is selectively oxygenated by COX-2 to form PGH2-
glycerol ester (PGH2-G) and HETE-glycerol esters (HETE-G) (52).  Notably, the 
oxygenation of 2-AG by COX-2 is as efficient as that of AA as evidenced by steady-state 
kinetic analysis indicating that AA and 2-AG have comparable kcat/Km values. In vitro, 
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the prostaglandin-like product of 2-AG oxygenation, PGH2-G, undergoes non-enzymatic 
isomerization to form PGD2-G and PGE2-G.  Conversion of 2-AG to PGH2-G has also 
been examined in RAW 264.7 murine macrophages, where exogenous 2-AG is rapidly 
converted to PGH2-G. PGD synthase expressed by the macrophages then acts on the 
endoperoxide intermediate to form PGD2-G (52). This finding prompted the investigation 
of the ability of PGH2-G, as well as PGH2-EA, to serve as substrates for additional 
prostaglandin synthases in cellular and subcellular systems (53). Kozak et al. reported 
that both PGH2-G and PGH2-EA are efficiently converted to D-, E- and I- series 
prostaglandin glycerol esters and ethanolamides, respectively, by the appropriate 
synthase enzymes (53). Although thromboxane synthase is able to catalyze the 
isomerization of PGH2-G, product formation is reduced approximately 20-fold when 
compared to the isomerization of the free acid, PGH2; this suggests that PGH2-G is a poor 
substrate for thromboxane synthase.  
 
             
Figure 3. Oxygenation of endocannabinoids by COX-2. 
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Endocannabinoid oxygenation in vivo. Concentrations of 2-AG exceeding the Km for 
oxygenation by COX-2 have been reported in the brain and various other tissues, 
suggesting that PG-G formation may occur under physiological conditions (54). 
Detection of endocannabinoid-derived prostanoids in vivo has been difficult, however, 
possibly due to the fact that PG-Gs can be hydrolyzed to form PGs indistinguishable from 
those formed by AA oxygenation. The first evidence for the formation of PG-Gs under 
physiologically relevant conditions came from studies in which stimulation of RAW 
264.7 cells with bacterial lipopolysaccharide (LPS) plus interferon-γ followed by the 
calcium ionophore ionomycin led to the production and extracellular release of low-
levels of PGD2-G (52). In similar studies, mouse peritoneal macrophages treated with 
LPS followed by zymosan generated PGE2-G and PGI2-G (55). Due in part to a 10-fold 
difference in the levels of 2-AG and AA released upon treatment with zymosan, the total 
amount of PG-Gs was approximately 1000-fold lower than those of traditional PGs; 
additional limiting factors in PG-G production are under investigation. Recently, 
endogenous PGE2-G has been isolated from a rat hind paw extract, further suggesting that 
2-AG-derived prostaglandin-like products are naturally occurring in vivo (56). 
 
Physiology of oxygenated endocannabinoids. Accumulating evidence suggests that PG-
EAs (or “prostamides") and PG-Gs have physiologic roles distinct from those of 
traditional prostaglandins. For example, PGE2-EA reduces the expression of IL-12p40 in 
activated macrophages and microglial cells (57). The parent endocannabinoid, AEA, also 
negatively regulates IL-12p40 production, thereby inhibiting the expression of the 
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cytokines, IL-12 and IL-23. The inhibitory effects of AEA and PGE2-EA on IL-12p40 are 
partially reduced by an EP2 receptor antagonist, but an EP4 receptor antagonist has no 
effect. These results indicate that the specific activation of EP2 may play a role in the 
downregulation of IL-12p40 induction by AEA and PGE2-EA. Further, these findings 
suggest that the endocannabinoid system could potentially be targeted in the treatment of 
autoimmune or chronic inflammatory diseases.  
A structural analog of PGF2α-EA, bimatoprost, is an ocular hypotensive agent 
marketed for the treatment of glaucoma and ocular hypertension. While neither 
bimatoprost nor PGF2α-EA exhibit significant activity at prostaglandin receptors, some 
have suggested that bimatoprost acts as a prostaglandin prodrug. However, extensive 
ocular distribution and metabolism studies indicate that bimatoprost exerts its effects as 
the intact, prostamide-like molecule (58). In fact, bimatoprost appears to signal through a 
heterodimer comprised of the F prostanoid (FP) receptor and a splice variant of the FP 
receptor with a truncated C-terminus (59).  
In agreement with the bimatoprost studies described above, endocanabinoid-
derived prostanoids generally have little or no affinity for traditional prostaglandin 
receptors, suggesting that orphan GPCRs or unknown heterodimeric complexes mediate 
the signaling of PG-Gs and PG-EAs.  In RAW 264.7 cells, low concentrations PGE2-G, 
but not PGE2, mobilize Ca2+, stimulate a transient increase in inositol 1,4,5 phosphate 
(IP3) levels, and activate PKC, leading to ERK phosphorylation (60). The activity of 
PGE2-G in RAW 264.7 cells was shown to be independent of hydrolysis to PGE2. 
Moreover, the affinity of PGE2-G for E prostanoid receptors was at least two orders of 
magnitude lower than that of PGE2, and binding to the thromboxane receptor, 
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prostacyclin receptor, D prostanoid receptor, or F prostanoid receptor was negligible. 
Together, these results imply that PGE2-G-mediated calcium moblization in RAW 264.7 
cells is not likely to occur through prostanoid receptor signaling.  
PGE2-G may also serve as a modulator of hippocampal synaptic transmission. In 
mouse hippocampal neurons, PGE2-G causes a concentration-dependent increase in the 
frequency of miniature inhibitory post-synaptic currents (mIPSCs) (EC50 = 1.7 µM) (61). 
The frequency of mIPSCs is also increased by PGD2-G, PGF2α-G, and PGD2-EA, but not 
by PGE2-EA and PGF2α-EA, whereas the endocannabinoids 2-AG and AEA reduce the 
frequency of mIPSCs. The ability of PG-Gs and PG-EAs to increase the frequency of 
mIPSCs is not likely related to hydrolysis to PGs or binding to PG receptors, as classical 
prostaglandins act to reduce the frequency of mIPSCs or have no effect. Calcium 
mobilization and MAPK-dependent phosphorylation are thought to be involved in the 
downstream signaling of this process, as treatment with an IP3 receptor agonist and a 
MAPK inhibitor blocks the PGE2-G-mediated increase in the frequency of mIPSCs. 
PGE2-G has also been shown to increase the frequency of miniature excitatory 
postsynaptic currents (mEPSCs) in mouse hippocampal neurons in culture (62). The 
enhanced glutamatergic transmission appears to be mediated by MAPK and IP3 signaling 
pathways. In cultured rat hippocampal neurons, PGE2-G caused a dose-dependent 
increase in terminal transferase dUTP nick end labeling (TUNEL) staining and time-
dependent cleavage of caspase-3 indicating that PGE2-G may be neurotoxic. 
There is some evidence that COX-2 derived PGI2-G may activate the nuclear 
receptor PPARδ in human vascular endothelial cells (63). Treatment of human umbilical 
vein endothelial cells expressing COX-2 with 2-AG leads to PPARδ activation, but this 
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effect does not appear to be mediated by the endocannabinoid itself, as cells lacking the 
CB1 and CB2 receptors exhibited levels of 2-AG–induced PPARδ transcription similar to 
those of WT cells.  However, both COX-2 and PGIS activity were required for 2-AG-
induced PPARδ activation by 2-AG, suggesting that 2-AG is converted to PGI2-G, which 
can then activate PPARδ. Importantly, the COX-2-PGI2-G-PPARδ pathway appears to 
lead to the attenuation of prothombotic tissue factor gene expression. 
The structural determinants of fatty acid oxygenation and inhibition of COX 
enzymes will be discussed in the remainder of this chapter. 	  
Structure of COX enzymes 
General COX structure.  The first three-dimensional structure of COX-1 was published 
in 1994, followed two years later by the crystal structure of COX-2 (64,65). To date, over 
30 structures of COX enzymes complexed with either substrates or inhibitors have been 
deposited in the Protein Data Bank. Following cleavage of the signal sequence, mature 
COX-1 consists of amino acid residues 25-600, with residues 33-586 showing clear 
electron density during crystallographic analysis (64). Similarly, residues 33-583 were 
resolved in the first crystal structure of COX-2; 35 amino acids at the C-terminus could 
not be located (65). A 14 amino acid deletion at the N-terminus of COX-2 causes the 
numbers of most COX-2 amino acids to be 14 units lower than those of COX-1, but by 
convention, the amino acids of both isoforms are referred to by the numbering of the 
initial COX-1 translation product. Comparison of the crystal structures of COX-1 and 
COX-2 reveals that the two isoforms have virtually superimposable structures with each 
COX monomer comprised of three domains: an epidermal growth factor (EGF)-like 
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domain, a membrane binding domain, and a large globular catalytic domain, which 
houses the cyclooxygenase (COX) and peroxidase (POX) active sites (Figure 4) (64-66). 
Consistent with gel-filtration studies, the COX enzymes are present as homodimers with 
an extensive dimer interface created by the EGF-like and catalytic domains (67).  
 
Domain architecture. COX does not span the lipid bilayer and is therefore termed a 
monotopic membrane protein. However, because detergent is required to dissociate the 
enzyme from the phospholipid bilayer, COX associates with the membrane as if it was an 
integral membrane protein. The membrane-binding domain (residues 73-116) is 
composed of four short amphipathic α-helices (A-D).  The helices are positioned 
approximately orthogonal to one another creating a hydrophobic surface ideal for 
insertion into a single face of the membrane bilayer. The helices of the membrane 
binding domain also surround a fairly large open area that has been dubbed the “lobby”, 
as it is thought that substrates and inhibitors must travel through this region to enter the 
active site located within the catalytic domain. 
The catalytic domain is structurally homologous to mammalian myeloperoxidase, 
suggesting that the COX enzymes evolved from soluble heme-dependent peroxidases 
(68). This principal domain of the COX monomer is largely composed of α-helical 
secondary structure. The POX active site is located in a solvent-accessible groove at the 
top of the catalytic domain while the COX active site lies at the vertex of a large, L-
shaped hydrophobic channel that extends from the membrane-binding domain into the 
catalytic domain.  Within the COX channel, the catalytic and membrane binding domains 
are separated by a constriction formed by three residues: Arg-120, Tyr-355 and Glu-524. 
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Figure 4. Three-dimensional structure of COX-2. The EGF-like domain is shown in 
purple, the membrane-binding domain in green and the catalytic domain is shown in 
grey. Heme (red sticks) is pictured bound in the peroxidase active site. PDB ID: 3PGH. 
 
 
The EGF-like domain is made up of a short sequence of amino acids at the N-
terminus (residues 34-72) of the protein, and its precise function remains unknown. 
However, it has been suggested that this domain may initiate or maintain interactions 
necessary for the insertion of COX into the membrane bilayer (68). 
 
POX active site.  As shown in Figure 5, the peroxidase active site is the location of heme 
binding where His-388 serves as the proximal heme ligand. Gln-203 and His-207 are 
positioned on the distal side of the heme, approximately 5 Å from the heme iron, but do 
not coordinate the metal (64). It is thought that these residues play a key role in the two-
electron reduction of the hydroperoxide substrate (20). Mutation of His-388, Gln-203, or 
His-207 causes a dramatic reduction in peroxidase activity (20,69). Of note, recent 
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studies show that, while the kcat/Km for peroxidase activity of G203V oCOX-1 is 17% that 
of WT enzyme, the mutant enzyme retains full COX activity and has a specific activity 
similar to that of WT suggesting that this Glu-203 is not essential for the initiation of 
COX catalysis (70).   
 In contrast to the majority of peroxidases, the POX active site of COX enzymes is 
largely exposed to solvent and can therefore accommodate large alkyl peroxide 
substrates. The openness of the POX active site also allows for relatively easy 
dissociation of small ligands, including heme, in and out of the active site cavity. For that 
reason, and due to the reactivity of the heme moiety, crystallization of substrates or 
products bound within the peroxidase active site has been difficult. Recently, the 2.0 Å 
crystal structure of oCOX-1 in complex with an analog of the non-steroidal anti-
inflammatory drug (NSAID) flurbiprofen provided the first view of a ligand bound in the 
POX active site (PDB ID: 1Q4G) (71). A detailed explanation of NSAIDs as COX 
inhibitors is provided below. However, in this particular structure, a glycerol molecule, 
used as a cyroprotectant, lies between Gln-203 and His-207 with the 1-hydroxyl group 
positioned roughly above the heme iron (Figure 5) (71). The 3-hydroxyl group 
participates in hydrogen bonding interactions with a water molecule coordinated to His-
207 (71). The location of this glycerol molecule is expected to mimic the binding 
conformation of the peroxide moiety of alkyl hydroperoxide substrates.  In fact, this 
structure was used as the basis for docking and molecular dynamics studies in order to 
predict the productive binding mode of the hydroperoxy endoperoxide intermediate, 
PGG2, within the POX active site (72).  
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Figure 5. Glycerol molecule bound within the POX active site of COX-1. Heme (red 
stick structure) is shown bound in the POX active site in addition to a glycerol molecule 
(blue and red) shown in ball-and-stick mode. Key residues for peroxidase activity are 
shown in turquoise. The catalytic tyrosine is shown in orange. PDB ID: 1Q4G.  
 
COX active site.  The COX active site channel spans 25 Å from the membrane binding 
domain to the interior of the catalytic domain; the catalytic center is located in the upper 
half of the channel from Arg-120 to Tyr-385. While the COX-1 and COX-2 active sites 
are relatively similar, the COX-2 active site is approximately 20-30% larger than that of 
COX-1 (Figure 6). The size difference is partially attributed to a single amino acid 
change (Ile-523 in COX-1, Val in COX-2) which limits access to a pocket off the main 
active site channel (73).	  	  Substitution of secondary shell residues, Ile-434 and His-513, in 
COX-1 for Val-434 and Arg-513 in COX-2 also contributes to the difference in active 
site size. 
His-388
His-207
Gln-203
Tyr-385
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Figure 6. Solvent accessible surfaces in the cyclooxygenase active site of COX-1 and 
COX-2. 
 
Structural basis of AA binding. Enzyme-substrate co-crystal structures in combination 
with mutagenesis studies provide a comprehensive understanding of the residues 
involved in critical COX-AA interactions.  To prevent substrate consumption during 
crystallographic analysis, COX can be stripped of the heme cofactor and reconstituted 
with Co3+-protoporphyrin IX to form an inactive pseudo-holoenzyme. The 3.0 Å crystal 
structure of AA bound to Co3+-protoporphryin IX-reconstituted oCOX-1 (Co3+-oCOX-1) 
showed that AA binds in an extended L-shaped conformation with the carboxylic acid 
coordinated to Arg-120 and Tyr-355 at the base of the active site (74). The aliphatic 
backbone extends into the catalytic site and makes a sharp bend near Tyr-385, positioning 
the ω-tail in a hydrophobic groove above Ser-530 and Leu-534 (74). This orientation 
places C-13 of AA directly beneath the phenolic oxygen of Tyr-385, allowing for the 
abstraction of the 13-proS hydrogen to initiate catalysis (Figure 7). The terminal carbon 
(C-20) sits directly against Gly-533, and a Gly-533 to alanine mutation renders COX-1 
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inactive against AA while COX-2 retains partial activity (74,75). However, mutation of 
Gly-533 to a larger valine or leucine residue abolishes COX-2 activity against AA. 
Interestingly, G533V and G533L COX-2 do have the ability to metabolize 18-carbon 
unsaturated fatty acids (e.g. linolenic and stearidonic acid), suggesting that binding of the 
ω-end of the fatty acid in this region of COX is an important determinant of substrate 
specificity (75). 
           
Figure 7.  Crystal structures of the productive and non-productive conformations of 
AA within the COX active site. A. In the productive binding mode of AA, the 
carboxylate moiety of AA (yellow ball-and-stick) participates in ion-pairing interactions 
with Arg-120 and hydrogen-bonding interactions with Tyr-355 (blue sticks) at the base of 
the COX-1 active site. The aliphatic backbone participates in hydrophobic interactions 
with several residues (turquoise sticks and not pictured) throughout the active site. The 
catalytic residue, Tyr-385, is shown in orange. PDB ID: 1DIY.  B. AA (pink ball-and-
stick) is shown in the non-productive or “inverted” conformation in the active site of 
COX-2. The carboxylate of AA is coordinated to Tyr-385 and Ser-530 at the top of the 
COX active site. PDB ID: 1CVU. 
 
 Crystallographic studies of AA bound to COX-2 reveal that the fatty acid can also 
occupy a non-productive binding conformation within the COX active site.  Kiefer and 
colleagues co-crystallized AA with H207A mCOX-2, a mutant enzyme lacking 
peroxidase activity, and observed the substrate bound in an “inverted” conformation in 
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which the carboxylic acid is coordinated to Tyr-385 and Ser-530 at the apex of the COX 
active site  (2.4 Å resolution)(76). In this orientation, C-13 is located greater than 10 Å 
away from the catalytic tyrosine and therefore, the chemistry required to initiate the COX 
reaction cannot occur. Crystallization of wild-type (WT) apo-COX-2 in the presence of 
AA resulted in a 3.0 Å structure with a combination of AA and prostaglandin bound in 
the COX active site. The orientation of AA is similar to the non-productive binding mode 
shown in Figure 7 while the prostaglandin molecule is bound in a manner analogous to 
the productive conformation of AA seen in COX-1. The carboxylic acid of PGH2 is 
located at the base of the active site near Arg-120 and Tyr-355 while the ω-end is 
positioned in the top channel of the active site; the endoperoxide ring is involved in 
hydrophobic interactions with Phe-381, Leu-384, Tyr-385, and Trp-387 (76). Currently, 
the physiological relevance of the non-productive or “inverted” binding mode of AA 
remains unknown.  
 In 2010, the Malkowski laboratory reported the 2.1 Å crystal structure of AA 
bound to Co3+-mCOX-2 (77). In the COX-AA crystal structures described above, the 
substrate is bound in relatively the same position in both active sites of the COX dimer. 
However, in this structure, the global conformation of AA is different in each monomer 
of the COX-2 homodimer. Interestingly, the non-productive binding mode of AA is 
observed in one monomer, but the productive conformation, similar to that of AA in the 
COX-1 active site, is seen in the partner monomer. The major difference in the 
productive binding of AA in the active site of COX-2 compared to COX-1 is the lack of 
an interaction between the guanidinium group of Arg-120 and the carboxylic acid of the 
substrate (77). This finding supports previous mutagenesis studies in which mutation of 
	   24	  
Arg-120 to Gln in COX-2 had no effect on the Km for AA, but the same mutation in 
COX-1 caused the Km for AA to increase 1000-fold compared to native enzyme (78,79).  
Hydrogen-bonding interactions between Tyr-355 and the carboxylic acid of AA occur in 
both COX-1 and COX-2.  
 Structural studies indicate that AA makes 49 interactions in the active site of 
COX-1 and participates in 54 interactions with COX-2 active site residues (74,77). 
Mutagenesis studies have helped to elucidate which of these interactions are critical for 
the proper positioning of the substrate during catalysis. Mutation of either Val-349 or 
Trp-387 causes a shift in the product profile of both COX-1 and COX-2, so that the 
enzyme forms an increased amount 11- or 15- HpETE (30-55%) while the amount of the 
bicyclic peroxide, PGG2, is correspondingly decreased (80). This suggests that these 
residues play a key role in facilitating the cyclization of the 11-peroxyl radical leading to 
the formation of the 9,11-endoperoxide group.   
 
Figure 8.  Overlay of AA bound in the COX active sites of WT and V349A/W387F 
Co3+-COX-1.  The structure of WT oCOX-1:AA is depicted as described in Figure 7 
(PDB ID: 1DIY). The structure of the double mutant enzyme (PDB ID: 1U67) is shown 
in dark slate blue. C1-C-13 of AA are shown in ball-and-stick mode, and major shifts are 
observed at C-3 through C-6 and C-11/C-12.  Mutations are noted in parentheses. 
Trp-387 (Phe)
Tyr-385
Ser-530
Leu-534
Gly-533
Val-349 (Ala)
Ile-523
Glu-524 Tyr-355
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A V349A/W387F Co3+-oCOX-1 double mutant produces greater than 85% 11R-HpETE, 
and a 3.1 Å crystal structure of the double mutant with AA bound in the COX active site 
reveals significant differences in the orientation of the substrate when compared to the 
WT COX-1:AA structure (Figure 8) (81).  It should be noted that no electron density was 
observed for C-13 through C-20 of AA in the V349A/W387F COX-1:AA structure. The 
catalytic tyrosine is within 3 Å of C-13 of AA, indicating that the enzyme is still 
catalytically competent. However, interactions between Val-349 and C-3 and C-4 of AA 
are lost as C-3-C-6 reposition to occupy the extra space created by the V349A mutation. 
In addition, mutation of Trp-387 to phenylalanine eliminates interactions between C-11 
and C-12, leading to greater conformational flexibility of the 11-peroxyl radical, so that 
the intermediate is no longer optimally aligned for endoperoxide formation (80,81). 
  The role of Ser-530 in promoting cyclization, as well as the control of 
prostaglandin stereochemistry, has also been studied by in-depth mutagenesis analyses. In 
oCOX-1, mutation of Ser-530 to threonine abolishes the production of PGG2 and leads to 
the formation of 15R-HpETE almost exclusively (80).  However, no detectable product 
formation is observed when the same mutation is made in the human COX-1 background. 
Substitution of Ser-530 with methionine, valine, leucine, or isoleucine in hCOX-1 also 
renders the enzyme inactive against AA (82). When Ser-530 is replaced with threonine in 
either murine or human COX-2, the ratio of prostaglandin to HpETE products is similar 
to that of WT, but there is a dramatic shift in the stereochemistry around C-15 toward the 
R-conformation. Mutation of Ser-530 to methionine or valine in COX-2 also results in 
almost complete stereochemical inversion of the oxygenation at C-15, as well as leads to 
increased amounts of HpETE products. Because both polar and non-polar substitutions 
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for Ser-530 alter the stereospecificity of the COX-2 reaction, it is likely that 
stereochemistry is partially controlled by steric interactions between the substrate and this 
region of the enzyme.  
 
Structural basis for the binding of omega-3 fatty acids within the COX active site.  
Although AA is the primary COX substrate, both COX-1 and COX-2 have the ability to 
oxygenate a range of 18 – 22 carbon n-3 and n-6 fatty acids with varying efficiencies.  
Here again, a combination of mutagenesis and crystallographic analysis has helped to 
elucidate key enzyme-substrate interactions. Crystal structures of eicosapentaenoic acid 
(EPA; 20:5 n-3) bound in the COX active site provide insight into the basis for the low 
rate of EPA oxygenation (< 5% for COX-1, ~30% for COX-2 with respect to AA). In the 
Co3+-oCOX-1:EPA structure (3.1 Å), EPA occupies an “L-shaped” conformation similar 
to the productive binding mode observed for AA in the oCOX-1 active site (Figure 9) 
(83). Like AA, the carboxylic acid of EPA forms a critical salt-bridge with Arg-120. 
However, the presence of an additional double bond (C17/C18) decreases the flexibility 
of the ω-tail of EPA in the hydrophobic groove above Ser-530, causing C-2 through C-10 
to adopt a strained conformation. Consequently, C-13 is misaligned with respect to Tyr-
385, precluding efficient initiation of the COX reaction. Mutation of Val-349, Ser-530, or 
Leu-534 further diminishes the oxygenation efficiency of EPA in a manner similar to that 
of AA. Interestingly, substitution of Phe-205 with leucine, at the top of the COX active 
site, dramatically increases the ability of COX-1 to metabolize EPA, presumably because 
the substrate is better accommodated in the larger active site of the mutant.  
	   27	  
   
Figure 9.  Binding of omega-3 fatty acids in the COX active site.  A: AA (yellow ball-
and-stick) and EPA (lime ball-and-stick) bind in an L-shaped conformation in the active 
site of COX-1. The ω-tail of EPA occupies a strained orientation so that C-13 is 
misaligned below the catalytic tyrosine (orange sticks) (PDB ID: 1DIY, 1IGX). B: AA 
(yellow), EPA (lime) and DHA (purple ball-and-stick) are shown in the productive 
conformation in the active site of COX-2. C-1 through C-9 of EPA are bound in a more 
extended conformation in COX-2 compared to COX-1 while C-1 through C-9 of DHA 
take on a coiled orientation like that of EPA in COX-1 (PDB ID: 3HS5, 3HS6, 3HS7). In 
both panels, constriction residues are shown in dark blue and additional key active site 
residues are shown in turquoise. 
  
The crystal structure of EPA bound within the active site of COX-2 has also been 
determined (2.4 Å). Like the structure for Co3+-COX-2:AA, Malkowski and colleagues 
observed EPA positioned in a non-productive binding conformation in the active site of 
one monomer and a productive conformation in the active site of the other monomer of 
the COX-2 dimer (77). The productive conformation of EPA in COX-2 is considerably 
different from the observed conformation in COX-1 (rmsd 2.28 Å).  In COX-2, the 
orientation of EPA is similar to what is observed for AA so that there is no critical 
interaction with Arg-120, and C-13 is appropriately aligned below Tyr-385 for catalysis 
(Figure 9). The proper positioning of C-13 for hydrogen abstraction in COX-2, compared 
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to the misalignment in COX-1, may explain why EPA is a more effective substrate for 
COX-2.  
In the same report, the Malkowski group described the 2.65 Å structure of 
docosahexaenoic acid (DHA; 22:6 n-3) bound to the active site of COX-2 (77).  In this 
case, DHA occupies a productive “L-shaped” conformation in both monomers where the 
carboxylate is located near Arg-120 and Tyr-355 at the base of the COX active site and 
the ω-tail sits in the hydrophobic groove above Ser-530; C-20 of DHA is adjacent to Ile-
377. To compensate for two extra carbons and the rigidity of two additional double bonds 
compared to AA, C-1 through C-9 of DHA bind in a compact, coiled orientation (Figure 
9). The conformation of DHA in the COX-2 active site is similar to that of EPA in the 
active site of COX-1. In this orientation, C-15 of DHA, rather than C-13, is positioned 
below the phenolic oxygen of Tyr-385, resulting in the inefficient oxidation of DHA 
compared to AA (~10%) and the generation of monohydroperoxy fatty acid products 
(84).  
 
Structural basis for COX-2 oxygenation of endocannabinoids.  The endocannabinoids, 
AEA and 2-AG, are selectively oxygenated by COX-2 to form prostaglandin 
ethanolamides and glycerol esters, respectively.  To date, a co-crystal structure of either 
AEA or 2-AG bound to COX-2 has not been published. However, the amino acid 
determinants of endocannabinoid oxygenation by COX-2 have been studied by 
mutagenesis. Substitution of the constriction site residue, Arg-120, for Gln resulted in a 
9-fold reduction in 2-AG oxygenation, whereas the oxygenation of AEA was reduced 
more than 3-fold compared to WT enzyme (51,85).  Further, mutation of Glu-524 to Leu 
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reduced the ability of COX-2 to oxygenate 2-AG, AEA, and also AA. Together, these 
results suggest that Arg-120 and Glu-524 at the constriction site play a critical role in the 
metabolism of endocannabinoids by COX-2. Interestingly, the third constriction site 
residue, Tyr-355, does not appear to be a determinant in endocannabinoid oxygenation.  
 Like AA, the endocannabinoids are not oxygenated by a Y385F mCOX-2 mutant 
enzyme, as an active tyrosyl radical at position 385 is required for catalysis. As described 
above, AA binds in an L-shaped conformation with its ω-tail inserted into a hydrophobic 
groove above Ser-530. The terminal carbon abuts Gly-533, and mutations that introduce 
steric bulk at position 533 dramatically reduce AA oxygenation. A Gly-533 to Val 
substitution also prevents the oxygenation of AEA and 2-AG. These results, combined 
with predicted interaction with constriction site residues, suggest that the 
endocannabinoids bind in a L-shaped conformation similar to that of AA.  
 The major difference in the active sites of COX-1 and COX-2 is the presence of a 
side pocket near the mouth of the active site in COX-2 that is not accessible in COX-1. 
The COX-2 side pocket is primarily comprised of Val-523, Arg-513, and Val-434. A 
COX-2 triple mutant, in which each of these residues has been mutated to its COX-1 
counterpart (V523I/R513H/V434I), exhibits a dramatic reduction in 2-AG and AEA 
oxygenation (approximately 75%), while AA metabolism is unaffected. In subsequent 
studies, Arg-513 was identified as the side pocket residue primarily responsible for COX-
2-selective oxygenation of endocannabinoids.  Based on these findings, Kozak et al. 
developed molecular models for 2-AG and AEA binding to COX-2 (Figure 10) (51,85).  
In the models, the carbonyl is positioned at the constriction site between Arg-120 and 
Tyr-355 with the primary alcohol located near Glu-524 and participating in hydrogen 
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bonding interactions with Arg-513. The hypothetical binding mode shown in Figure 10 is 
supported by structure-activity studies which indicate that the primary hydroxyl moiety 
of 2-AG and AEA is an important determinant in the binding of these endocannabinoids 
to COX-2 (51,85).  
 
Figure 10. Computational models of 2-AG and AEA bound in the COX-2 active site. 
Reproduced from (85) and (51). 
 
 
Mechanisms of NSAID action 
 
Discovery of NSAIDs. Ancient civilizations documented the use of natural products in the 
treatment of pain, fever, and inflammation.  The Ebers papyrus, arguably the world’s 
oldest preserved medical text, indicates that ancient Egyptians used dried myrtle leaves to 
treat pain and fever as early as 1550 BC. The Greek physician Hippocrates recognized the 
analgesic and anti-pyretic properties of willow bark and leaf extracts in the 5th century 
BC. In addition to the Egyptians and the Greeks, it appears that Roman, Native 
American, African, and Chinese civilizations utilized these plant extracts for medicinal 
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purposes. Reverend Edward Stone published the first scientific record of the anti-pyretic 
effects of willow bark in his presentation to the Royal Society of London in 1763.  
In 1829, the French pharmacist Henri Leroux identified salicin, the glucoside of 
salicylic alcohol, as the active ingredient in willow bark. Salicin can be modified to 
generate salicylic acid, but willow bark was difficult to obtain and purification from plant 
extracts was expensive so the supply of salicylic acid was limited (86).  However, by the 
mid 19th century, Koble and Lautemann developed a method for the industrial production 
of salicylic acid from phenol, thereby facilitating its use by the general population in the 
treatment of pain and fever.  To provide sufficient quantities of salicylic acid, the first 
drug factory, Salicylic Acid Works, was built in 1874. The widespread use of salicylic 
acid revealed its disadvantages; the low potency of the drug required patients to ingest 
several grams of the bitter compound per day, leading to gastric irritation and poor 
tolerance in many.  To circumvent this problem, Felix Hoffman, a chemist at Friedrich 
Bayer and Co., developed acetylsalicylic acid. By acetylating the hydroxyl group of 
salicylic acid, Hoffman created a more palatable form of the drug with improved gastric 
tolerability. In 1899, acetylsalicylic acid was marketed by Bayer as aspirin, and soon 
became the world’s best-selling drug.   
 
Figure 11. Chemical structures of salicilin, salicylic acid, and aspirin. 
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Animal models of pain and inflammation allowed the identification of several 
additional “aspirin-like” drugs, known today as non-steroidal anti-inflammatory drugs 
(NSAIDs), but the mechanism of action of these anti-inflammatory agents remained 
unclear until 1971.  Upon the discovery that treatment of guinea pig lung homogenates 
with aspirin, sodium salicylate, or indomethacin causes a dose-dependent decrease in 
prostaglandin biosynthesis, sir John Vane concluded that NSAIDs exert their activity by 
inhibiting the enzyme responsible for prostaglandin production; the enzyme was later 
dubbed COX (87).  Vane’s findings were published alongside those of Smith and Willis, 
who observed that treatment of platelets with aspirin led to inhibition of prostaglandin 
biosynthesis (88).  
 
Aspirin. Acetylsalicylic acid (aspirin) blocks prostaglandin production in both a time- and 
concentration-dependent manner (89). Notably, aspirin covalently modifies the COX 
enzymes as evident by the incorporation of radioactivity into the protein when incubated 
with [acetyl-3H]aspirin (90,91). The active site residue Ser-530 was determined to be the 
single site of acetylation by aspirin, and the rate of acetylation closely corresponds to the 
rate of irreversible COX inactivation (91,92).  Mutation of Ser-530 to alanine has no 
significant effect on COX activity, indicating that this residue is not essential for 
substrate binding or catalysis (93). However, S530A COX is not susceptible to covalent 
inhibition by aspirin, confirming that the hydroxyl moiety at position 530 is required for 
acetylation and subsequent irreversible inactivation of the enzyme by aspirin.   
 The crystal structure of COX-1 inactivated by the aspirin analog, 2-
bromoacetoxy-benzoic acid, shows that acetylation of Ser-530 leads to significant steric 
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hindrance within the active site, effectively blocking substrate from interacting with the 
catalytic residue, Tyr-385, and thereby preventing catalysis (94).   The bromoaspirin 
analog was shown to interact with COX-1 in a manner analogous to aspirin, and was 
employed in these studies so that the electron-dense halogen atom could be 
unambiguously located in a low-resolution electron density map (94). Upon acetylation 
of Ser-530, the bromoacetyl group occupies two rotameric states: in the primary 
conformer, the bromoacetyl group is positioned directly below Tyr-385 fully blocking the 
active site channel (Figure 12), while in the minor conformer, the bromoacetyl group 
extends into the hydrophobic groove above Ser-530, resulting in less hindrance of the 
main active site channel (not shown).  
                                       
Figure 12.  Crystal structure of bromoacetylated oCOX-1. A. Chemical structures of 
bromoaspirin analog 2-bromoacetoxy-benzoic acid. B. The primary conformer of the 
bromoacetyl serine and the by-product of the acetylation reaction, salicylic acid, are 
shown in magenta sticks within the COX-1 active site. The carboxylic acid moiety of 
salicylic acid participates in key interactions with Arg-120, while the carbonyl oxygen of 
the bromoacetyl group hydrogen-bonds to the phenolic oxygen of Tyr-385 (orange sticks) 
at the apex of the COX active site. (PDB ID: 1PTH) 
 
!"#$%&'
!("$%&)
*+,$)-%
.,/$)%0
!("$%))
1"2$3-4
5+/$)-0
16$7,"$)%4
OH
O
O
O
OH
O
O
CH2BrO
Aspirin
Bromoaspirin
A B 
	   34	  
Salicylic acid acts as the leaving group during the acetylation of COX-1 by aspirin. As 
shown in the oCOX-1:bromoaspirin crystal structure, salicylic acid is present within the 
COX active site approximately 5 Å away from the site of acetylation. The carboxylic acid 
moiety participates in ion-pairing interactions with Arg-120 at the base of the active site 
channel, and mutation of Arg-120 to glutamine or alanine results in a dramatic reduction 
in acetylation of COX upon treatment with aspirin (95). Mutagenesis studies performed 
within the COX-2 background indicate that Tyr-385 is also a critical determinant for 
acetylation by aspirin, as the extent of acetylation observed in Y385F COX-2 is reduced 
to levels similar to those observed in S530A mutant enzymes. In agreement with these 
studies, the oCOX-1:bromoaspirin crystal structure shows that the carbonyl oxygen of the 
bromoacetyl group participates in hydrogen-bonding interactions with the phenolic 
oxygen of Tyr-385. It has been proposed that this interaction acts to localize the acetyl 
group of aspirin near Ser-530 as well as to stabilize the negative charge of the tetrahedral 
intermediate of acetylation leading to increased reactivity (95). 
A methionine substitution at Ser-530 most closely mimics the acetylation by 
aspirin, as three non-hydrogen atoms are added in both cases. Similar to the results 
obtained with S530M COX-1 and COX-2, aspirin acetylation inactivates oCOX-1 and 
causes the major product of the COX-2 reaction to become 15R-HpETE as opposed to 
15S-PGG2 (96). The ability of COX-2 to retain some enzymatic activity following 
acetylation by aspirin may also be related to the larger active site of COX-2 compared to 
COX-1.  In support of this hypothesis, mutation of the residues that make up the COX-2 
side pocket (Val-523, Arg-513, and Val-434) to the corresponding residues in COX-1 
(Ile-523, His-513, and Ile-434) eliminates product formation by COX-2 upon treatment 
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with aspirin (97). It has been suggested that the larger COX-2 active site may lead to a 
change in the preferred rotameric state of the acetyl-serine side chain of COX-2 from that 
observed in the COX-1 crystallographic studies described above (94).  
The irreversible inactivation of COX-1 by aspirin in the platelet is exploited 
therapeutically in cardiovascular prophylaxis. The cardioprotective effect of aspirin is 
attributed to sustained inhibition of COX-1 in the platelet, effectively preventing the 
biosynthesis of the vasoconstrictor, TXA2. Because platelets are enucleated cells and 
cannot generate new COX-1 following acetylation, TXA2 synthesis is blocked for the 
entire lifetime of the platelet. At low doses, aspirin does not dramatically affect the 
formation of the vasodilator, PGI2, by COX-2 in the vascular endothelium, which can 
synthesize new enzyme molecules to replace those inactivated by acetylation (98).  
 
Phenylpropionic acids. Aspirin is the only clinically used COX inhibitor to covalently 
modify the enzyme; all other NSAIDs are classified as either competitive and rapidly 
reversible or time-dependent, tight-binding and poorly reversible (89). The 
phenylpropionic acids, mefenamic acid and ibuprofen, interact with COX in a single-step 
kinetic mechanism characterized by the dissociation constant, KI. Meclofenamic acid and 
flurbiprofen are structurally analogous to mefanamic acid and ibuprofen, respectively, but 
associate with the COX enzymes via a two-step mechanism in which the initial 
bimolecular association of the inhibitor with the enzyme is followed by a slower 
intramolecular step that results in a more tightly bound complex (eq 1) (89).  
 
 
(eq 1) 	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 While ibuprofen and flurbiprofen exhibit different kinetic modes of inhibition, co-
crystal structures indicate that the two inhibitors bind in a similar fashion within the COX 
active site (Figure 13) (64,65,99). As seen for AA, the carboxylic acid moiety of the 
inhibitor is positioned near the constriction site, where it participates in key interactions 
with Arg-120 and Tyr-355. Mutagenesis studies further demonstrate that an ion-pair with 
Arg-120 and a hydrogen bond with Tyr-355 are critical for potent inhibition of COX-1 
and COX-2 by both ibuprofen and flurbiprofen (78,79).  In addition, Tyr-355 is proposed 
to play a role in the stereospecificity of binding of 2-phenylpropionic acids. Although the 
majority of NSAIDs in this family are marketed as racemic mixtures, the (S)-enantiomer 
is significantly more potent than the (R)-enantiomer in vivo. The strict stereoselectivity is 
thought to arise from unfavorable steric interactions with the bulky phenolic side chain of 
Tyr-355 when the methyl group of the inhibitor is in the (R)-conformation. Bhattacharyya 
and colleagues provided support for this hypothesis in finding that decreasing the size of 
the side chain at position 355 (Tyr to Phe) results in significantly less specificity toward 
(R)- and (S)-ibuprofen compared to WT enzyme (78). 
 While phenylpropionic acids appear to be anchored within the COX active 
site by interactions between the carboxylic acid moiety and constriction site residues, the 
inhibitors make several contacts with additional protein residues in the active site cavity. 
The (S)-α-methyl group of 2-arylpropionic acids inserts into a small hydrophobic cleft 
near the base of the active site allowing it to participate in van der Waals interactions 
with Val-349 and Leu-359 (64,65). The distal portion of each inhibitor (i.e. the 
substituent on the phenyl ring) contacts amino acid residues located near the apex of the 
COX active site. Ibuprofen, the smallest NSAID of its class, is the exception, as the 
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isobutyl group is greater than 3.7 Å from neighboring protein residues (99). The 
fluorinated ring of flurbiprofen participates in van der Waals interactions with Val-349 
and Ala-527. The fluorine atom itself contacts Ile-523 in COX-1, but makes no such 
interaction with the corresponding valine residue in COX-2 (65). In addition to several 
hydrophobic interactions, the unsubstituted phenyl ring of flurbiprofen contacts Ser-530 
and stacks against Tyr-385 in both COX-1 and COX-2 (65,99).   
 
 
Figure 13. Phenylpropionic Acids. A. Chemical structures of phenylpropionic acids. B. 
Crystal structure of ibuprofen in the active site of oCOX-1 (1EQG). Ibuprofen (purple) 
interacts with constriction site residues Arg-120 and Tyr-355 (blue). C. Crystal structure 
of flurbiprofen (green) in the mCOX-2 active site (3PGH). Key active site residues are 
shown in turquoise and the catalytic tyrosine is shown in orange.  
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The unsubstituted ring of flurbiprofen approaches Leu-384 at the apex of the 
COX channel; Leu-384 is oriented differently in the active sites of COX-1 and COX-2 
because of an amino acid change in the neighboring residue at position 503 (Phe in COX-
1, Leu in COX-2). This substitution results in the presence of a small alcove in the COX-
2 active site located above the phenyl ring of flurbiprofen. Based on the hypothesis that 
introduction of a lipophilic substituent at the 3’-position of the phenyl ring could be 
accommodated in the active site of COX-2, but not COX-1, Bayly and co-workers 
generated a series of potent and COX-2-selective flurbiprofen analogs (100). These 
studies provide a clear example of the importance of structural information in the rational 
design of COX inhibitors.  
 While crystallographic studies reveal critical information regarding the molecular 
determinants of inhibitor binding within the COX active site, they do not provide a 
complete explanation for the kinetic differences between competitive, reversible and 
slow, tight-binding inhibitors.  As previously mentioned, flurbiprofen interacts with both 
COX-1 and COX-2 in a time-dependent, poorly reversible manner. In contrast, the 
flurbiprofen methyl ester binds to COX via a single-step mechanism like ibuprofen and 
mefenamic acid. Comparison of the co-crystal structures of flurbiprofen and methyl 
flurbiprofen bound to COX-1 reveals minor differences in the orientation of the inhibitors 
within the COX active site, but all major enzyme-inhibitor interactions are maintained 
(99).  These studies illustrate that the structural basis for time-dependent inhibition is not 
related to a global conformational rearrangement of the enzyme structure and may be 
unique to each NSAID.  
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 The 2-arylpropionic acid, naproxen, is one of the oldest and most widely used 
NSAIDs. Interestingly, naproxen is the only member of its class to be used exclusively as 
the (S)-enantiomer in the clinic. Previous kinetic studies suggest that naproxen binds to 
COX-1 in a time-independent manner but displays “mixed” inhibition for COX-2; 
“mixed”	   inhibition is defined as an initial time-dependent loss of enzyme activity 
followed by a non-zero plateau (101). A detailed investigation of the molecular basis for 
COX inhibition by naproxen will be presented in Chapters II and III of this dissertation.  
 
Arylacetic acids.  The indole based arylacetic acid, indomethacin, was first described as a 
time-dependent inhibitor of prostaglandin biosynthesis by Rome and Lands in 1975 (89). 
Similar to that of flurbiprofen, inhibition of COX by indomethacin is characterized as 
slowly reversible, rather than covalent, as intact inhibitor can be recovered following 
prolonged incubation with either COX enzyme (102). Following these early reports, in-
depth studies have been performed in an effort to elucidate the molecular determinants of 
time-dependent COX inhibition by indomethacin. Examination of the COX-
2:indomethacin co-crystal structure shows that the inhibitor is bound completely within 
the COX active site (Figure 14). As for the majority of carboxylate-containing NSAIDs, 
the carboxylic acid moiety is involved in critical interactions with Arg-120 and Tyr-355 
at the constriction site. Salt-bridge formation between indomethacin and Arg-120 is 
essential for time-dependent inhibition of COX-1, but not COX-2, and as a result, 
conversion of the carboxylate moiety to various esters or amides generates potent COX-
2-selective indomethacin derivatives (103) (104,105).  
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 An important determinant of time-dependent inhibition by indomethacin appears 
to be the insertion of the 2′-methyl group into a small hydrophobic pocket formed by Val-
349, Ala-527, Ser-530, and Leu-531 (106). Mutation of Val-349 to alanine increases the 
size of this pocket and renders the enzyme more sensitive to inhibition by indomethacin; 
decreasing the size of the pocket by mutation of Val-349 to leucine correspondingly 
decreases the potency of indomethacin. Interestingly, indomethacin exhibits significant 
reversibility in its inhibition of V349L COX-2 compared to WT. These mutagenesis 
studies have been corroborated by structure-activity studies showing that removal of the 
2′-methyl group of indomethacin leads to poor and readily reversible inhibition of both 
COX-1 and COX-2.  
Although binding of the 2′-methyl group in the hydrophobic pocket appears to be 
critical for the formation of the tightly bound enzyme-inhibitor complex, additional 
interactions help to anchor indomethacin within the COX active site. Inspection of the co-
crystal structure of indomethacin in complex with COX-2 reveals that the o-methoxy 
group projects into a relatively large cleft comprised of Ser-353, Tyr-355, and Val-523 
(65).  The para-chlorobenzoyl group binds at the apex of the COX active site so that the 
chlorine atom interacts with Leu-384, and the benzoyl oxygen interacts with the side 
chains of Ser-530 and Val-349; hydrophobic interactions with Leu-384, Phe-381, Tyr-
385, and Trp-387 act to stabilize the benzoyl group. 
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Figure 14. Binding of indomethacin and diclofenac in the mCOX-2 active site. A. 
Indomethacin (yellow) coordinates to constriction site residues Arg-120 and Tyr-355 
(blue). The 2′-methyl group inserts into a small hydrophobic pocket comprised of Ser-
530, Val-349, Leu-531, and Ala-527 (turquoise) (PDB ID: 4COX). B. Diclofenac 
(maroon) binds in an inverted conformation in the mCOX-2 active site with the 
carboxylate hydrogen-bonded to Ser-530 and Tyr-385 (PDB ID: 1PXX).  
 
 Diclofenac, like indomethacin, exhibits potent time-dependent inhibition of COX-
1 and COX-2, but the binding mode of diclofenac is distinct among arylcarboxylic acid 
inhibitors. In this case, the inhibitor is positioned in an inverted conformation with its 
carboxylic acid hydrogen-bonded to Ser-530 and Tyr-385 at the top of the active site 
channel (Figure 14) (107). Mutation of constriction site residues at the base of the active 
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site does not affect diclofenac’s inhibition of COX-2, whereas mutation of Ser-530 to 
alanine or methionine essentially abolishes its inhibitory activity (107,108). Although the 
strong hydrogen bonds to Tyr-385 and Ser-530 represent the only polar interactions 
between diclofenac and COX-2, the inhibitor makes hydrophobic contacts with several 
residues throughout the active site. The phenylacetic acid ring is encompassed by Tyr-
385, Trp-387, Leu-384, and Leu-352, while the dichlorophenyl group participates in van 
der Waals interactions with Val-349, Ala-527, Leu-531, and Val-523 (107). Despite 
being similar in size and chemical composition, indomethacin and diclofenac display 
dramatically different binding modes within the COX-2 active site clearly demonstrating 
that each individual NSAID takes advantage of a unique set of active site residues in the 
formation of a tightly-bound enzyme-inhibitor complex. However, both NSAIDs appear 
to be anchored within the COX active at two primary locations. As described, the 
carboxylate of indomethacin is coordinated to constriction site residues while the 2′-
methyl group binds in a hydrophobic depression bordered by Val-349.  Diclofenac also 
has two major points of interaction in the COX active site as one of the chlorine atoms 
inserts into the hydrophobic pocket occupied by the of 2′-methyl group indomethacin and 
the carboxylate participates in H-bonding interactions with Ser-530 and Tyr-385. 
 
Development of COX-2-selective inhibitors. Traditional NSAIDs, like those described 
above, are non-selective inhibitors of COX-1 and COX-2. The difference in the 
expression profiles of the COX enzymes suggests that the benefits of NSAID use, namely 
anti-inflammatory, analgesic, and antipyretic effects, arise from inhibition of COX-2, 
while deleterious side effects are associated with COX-1 inhibition. Side effects vary 
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greatly among individuals, and include gastrointestinal, liver, kidney, and nervous system 
toxicity. It was predicted that a COX-2-selective inhibitor would prevent inflammation 
without these undesired effects, specifically gastrointestinal toxicity. This hypothesis has 
since been validated in both animal models and human clinical trials, demonstrating that 
COX-2-selective inhibitors are anti-inflammatory and non-ulcerogenic (109-111). 
 
Diarylheterocycles. The majority of COX-2-selective inhibitors used in the clinic belong 
to the diarylheterocycle structural class (Figure 15). In its search for novel anti-
inflammatory agents with improved gastrointestinal safety, Dupont-Merck developed an 
aryl methyl sulfonyl inhibitor, DuP 697, prior to the discovery of COX-2. The finding 
that DuP 697 blocked prostaglandin biosynthesis in macrophages but not platelets 
suggested fundamental differences in its interactions with the COX enzymes in those cell 
types (112). This was substantiated by the discovery of COX-2 and the demonstration of 
its presence in macrophages (113). As such, DuP 697 acted as the principal lead 
compound in the development of COX-2-selective inhibitors culminating in the 
introduction of several diarylheterocycles to the market. 
 Diarylheterocycles, including DuP 697, appear to be rapid, reversible inhibitors of 
COX-1, but time-dependent, tight-binding inhibitors of COX-2 (114). Fluorescence 
quenching analysis has been used to directly monitor the kinetics of association of 
selective inhibitors to the COX enzymes, and indicates that diarylheterocycles follow a 
three-step mechanism of inhibition in which a fast bimolecular reaction is followed by 
two unimolecular steps (115,116). Traditional kinetic analysis of steady-state and time-
dependent COX inhibition by the diarylheterocycles valdecoxib and celecoxib provided 
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further evidence for the three-step kinetic model (117). The third step of the inhibitor 
interaction with COX-2 results in the formation of a pseudo-irreversible complex and is 
thought to confer selectivity (116,117). 
 Structure-activity studies show that the presence of two aromatic rings at adjacent 
positions on a central heterocycle or carbocycle, with a 4-sulfunoamide or 4-
methylsulfone substitution on one phenyl ring is critical for potent and selective 
inhibition of COX-2 (118). In support of this observation, mutagenesis and X-ray 
crystallography studies indicate that the final step of COX-2-diarylheterocycle 
association is the binding of the sulfonamide or sulfone moiety within a small pocket near 
the mouth of the COX-2 active site.  The co-crystal structure of the celecoxib analog SC-
558 bound to mCOX-2 clearly shows the insertion of the phenylsulfonamide moiety into 
this side pocket while the second phenyl ring binds in a hydrophobic cavity at the apex of 
the COX-2 active site bordered by Phe-381, Leu-384, Tyr-385, Trp-387, Phe-518, and 
Ser-530 similar to the binding of the phenyl ring of flurbiprofen and the benzoyl group of 
indomethacin (65).  
Hydrophobic residues, including Leu-352, Tyr-355, Phe-518, and Val-523, 
surround the phenyl ring of the phenylsulfonamide moiety, while the sulfonamide 
interacts with His-90, Gln-192, and Arg-513. This region of the enzyme is less accessible 
in COX-1 largely due to the substitution of isoleucine for valine at position 523. Mutation 
of Val-523 to Ile in COX-2 eliminates time-dependent inhibition of COX-2 by 
diarylheterocycles but has only modest effects on the potency of traditional NSAIDs, 
suggesting that Val-523 is a critical determinant of selectivity in inhibitor binding 
(119,120). Secondary shell substitutions (Arg-513 for His and Val-434 for Ile) appear to 
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contribute to the accessibility of the COX-2 side pocket and therefore play a role in the 
selectivity of the diarylheterocycle class (65,121).  
  Recent reports indicate that the COX-2-selective inhibitor celecoxib can actually 
bind tightly within the active site of COX-1 (122). Overall, crystallographic studies 
indicate celecoxib adopts a similar conformation in COX-1 to that of SC-558 in the 
COX-2 active site. To accommodate the phenylsulfonamide moiety of celecoxib, Ile-523 
adopts an extended rotamer conformation resulting in a shift in the positions of side chain 
residues 513-515 within the side pocket. While the sulfonamide group of SC-558 
participates in hydrogen-bonding interactions with Arg-513 in COX-2, no such 
interactions occur between celecoxib and His-513 in COX-1.  However, short hydrogen 
bonds are predicted to occur between the amide nitrogen of the sulfonamide moiety of 
celecoxib and Gln-192 and the backbone of Leu-352.  The crystal structures of the COX-
2 selective inhibitors nimesulide and indomethacin serinol amide bound within the active 
site of COX-1 also illustrate the ability of Ile-523 to adopt an alternate conformation to 
allow binding within the side-pocket region (123,124).  
 
Lumiracoxib. Lumiracoxib, a close structural analog to diclofenac, represents the only 
example of a COX-2-selective inhibitor of the arylacetic acid class to be approved for use 
in the clinic. Crystallographic studies indicate that lumiracoxib binds in an inverted 
conformation similar to that of diclofenac in which the carboxylic acid is coordinated to 
Ser-530 and Tyr-385 at the apex of the COX active site. Selective inhibition of COX-2 by 
lumiracoxib is thought to arise form the insertion of the methyl group located on the 
phenylacetic acid ring into a small groove near Leu-384 at the top of the COX-2 active 
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site; in COX-1, bulky secondary shell residues surround Leu-384, restricting access to 
this region of the enzyme. Structure-activity studies illustrate that the presence of the 
methyl group is critical for COX-2 selectivity, as a des-methyl derivative of lumiracoxib 
is equally effective against COX-1 as it is COX-2 (125). A primary determinant of 
potency appears to be the binding of the chlorine atom of lumiracoxib within the small 
hydrophobic pocket comprised of Val-349, Ala-527, Ser-530, and Leu-531 in a manner 
analogous to that of the 2′-methyl group of indomethacin and the chlorine atom of 
diclofenac.        
 
 
 
Figure 15. COX-2-selective inhibitors. A. Chemical structures of COX-2-selective 
inhibitors. B. Crystal structure of the celecoxib analog, SC-558 (red-orange), bound 
within the COX-2 active site. The sulfonamide moiety is inserted into the COX-2 side 
pocket lined by Val-523 and Arg-513 (PDB ID: 6COX). C. Crystal structure of celecoxib 
(green) bound in the active site of COX-1. Ile-523 adopts an extended conformation to 
allow for the binding of the sulfonamide moiety (PDB ID: 3KK6). 
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Partnering between COX monomers. The first evidence of cooperativity between COX 
monomers was the discovery that one molecule of a slow, tight-binding inhibitor (e.g. 
flurbiprofen, indomethacin) is sufficient to block substrate metabolism by the entire COX 
homodimer, suggesting that this class of inhibitors can achieve maximal inhibitory 
activity by binding to a single monomer (102).  Preparation of COX heterodimers in 
which a WT hCOX-2 monomer was coupled to a monomer containing a mutation within 
the COX active site allowed for further investigation of possible cross-talk between COX 
subunits (126). Gly-533 is critical for the proper positioning of AA during catalysis and 
as such, G533A COX homodimers exhibit minimal catalytic activity compared to WT 
COX (75). However, the WT/G533A COX heterodimer is able to metabolize AA in a 
manner comparable to WT (126). The slow, tight-binding inhibitor, flurbiprofen is not an 
effective inhibitor of the R120Q/R120Q COX homodimer but exhibits potent, time-
dependent inhibition of the WT/R120Q heterodimer (126).  Together, these studies imply 
that COX enzymes exhibit half-of-sites reactivity, with only a single functioning 
monomer during catalysis. These findings are consistent with recent reports by the 
Malkowski group (described above) in which substrates occupy alternate conformations 
in the each COX active site of the biological dimer; further suggesting that only one 
monomer is functional at any given time. 
 Recently, structural studies have been performed in an attempt to elucidate the 
mechanism of communication between partnered COX monomers. Cross-linking studies 
indicate that the loop containing Ser-126 and Pro-127 as well as the loop containing Ser-
541 and Ala-543, both located at the dimer interface of COX-2, are altered during 
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inhibitor binding (127).  The crystal structure of celcoxib bound to COX-1 provides 
further evidence for a conformational change at the dimer interface. In the oCOX-
1:celecoxib structure, one monomer is 100% occupied by celecoxib while the partner 
monomer is approximately 50% occupied. In the partially unoccupied monomer, positive 
difference density (Fo-Fc) revealed an alternate conformation of the loop containing 
residues 121-129 (Figure 16)(122). In agreement with the cross-linking studies, when the 
loop is present in the alternate conformation, Ser-126 closely neighbors Glu-543 as 
shown in Figure 16.  
 
         
 
Figure 16. Alternate conformations of residues 121-129 at the dimer interface in the 
oCOX-1:celecoxib crystal structure.  Reproduced from (122). 
 
Movement of the 123-129 loop is also visible in the crystal structure of flurbiprofen 
bound to the WT/R120Q COX-1 heterodimer further indicating that this mobile loop may 
play a key role in the cross-talk between COX monomers (123).  
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COX-2 inhibitors and cardiovascular toxicity. The Vioxx Gastrointestinal Outcome 
Research (VIGOR) study provided the first evidence for an increased risk of 
cardiovascular events associated with the use of COX-2-selective inhibitors (110). In the 
VIGOR trial, the efficacy and safety of the potent and highly selective inhibitor, 
rofecoxib (Vioxx), was evaluated in comparison to the non-selective NSAID, naproxen, 
in patients with rheumatoid arthritis. Rofecoxib proved to be equally efficacious to 
naproxen with a reduced number of GI adverse events. However, patients treated with 
rofecoxib exhibited a 4-fold increase in acute myocardial infarction compared to those 
treated with naproxen. The long half-life of naproxen in humans leads to sustained 
inhibition of COX-1-driven production of the prothrombotic and atherogenic, TXA2 
(128). When administered at doses of > 500 mg twice daily, the biosynthesis of platelet-
derived TXA2 is inhibited throughout the dosage interval, and the inhibition of platelet 
COX-1 at the end of the dosage interval approaches but does not equal that of aspirin. As 
such, authors of the VIGOR study claimed that rofecoxib was neutral with regard to 
cardiovascular toxicity, and that the apparent increased risk was reflective of a 
cardioprotective effect of naproxen. It should be noted that this aspirin-like sustained 
inhibition of platelet COX-1 is not observed when lower doses of naproxen (e.g. 220 mg 
twice daily) are administered.  The Celecoxib Long-term Arthritis Safety Study (CLASS) 
trial was a similar study in which celecoxib (400 mg twice daily) was compared to 
diclofenac and ibuprofen in patients with osteoarthritis or rheumatoid arthritis (111). 
Initial reports indicated that celecoxib was associated with fewer upper gastrointestinal 
events compared to the traditional NSAIDS, but no statistically significant differences 
were observed after twelve months of follow up (129). This is consistent with reports that 
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celecoxib and diclofenac show a similar degree of COX-2 selectivity in human whole 
blood assays (130).  Furthermore, no significant differences in the incidence of 
cardiovascular events between celecoxib and the comparator non-selective NSAIDs were 
observed.  
 Colon polyp recurrence trials allowed for further evaluation of a potential 
cardiovascular hazard associated with COX-2 inhibitors. COX-2 is overexpressed in 
human colon cancers and is thought to play a role in tumorigenesis. Therefore, COX-2-
selective inhibitors are attractive candidates for novel chemopreventive agents.  The 
Adenomatous Polyp Prevention on Vioxx (APPROVE) trial evaluated the recurrence of 
polyps in individuals treated with rofecoxib (25 mg) versus placebo. The study showed a 
clear reduction in polyp recurrence (24%) in patients treated with rofecoxib after three 
years. However, treatment with rofecoxib also resulted in a roughly 2-fold increase in 
cardiovascular events, including myocardial infarction and stroke, compared to placebo 
(131,132).	   The cardiovascular side effects reported in the APPROVE trial led to the 
immediate withdrawal of rofecoxib from the market. Similarly, the Adenoma Prevention 
with Celecoxib (APC) trial measured polyp recurrence in patients receiving either 200 or 
400 mg celecoxib twice daily compared to placebo and reported a dose-dependent 
reduction in the recurrence of polyps following treatment with celecoxib. Cardiovascular 
events also increased in a dose-dependent manner with a 2.6-fold increase in patients 
allocated to low-dose celecoxib and a 3.4-fold increase in the high-dose group. Together, 
these trials illustrate the potential for COX-2-selective inhibitors as an effective therapy 
in the prevention of colon polyp recurrence but also establish that prolonged use of COX-
2 inhibitors is associated with an increased risk of adverse cardiovascular events.  
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 It has been hypothesized that the cardiovascular toxicity of COX-2-selective 
inhibitors is thought to arise from the inhibition of the COX-2-driven production of the 
anti-thrombotic and anti- atherogenic PGI2 or PGI2-G by vascular endothelial cells 
(63,133).  As such, there is some debate as to whether or not the cardiovascular risk 
associated with selective COX-2 inhibitors extends to non-selective NSAIDs, which also 
block PGI2 biosynthesis. Long-term, placebo-controlled studies of significant power must 
be conducted in order to make definitive conclusions regarding the cardiovascular 
outcomes associated with the use of non-selective NSAIDs. However, evolving data from 
meta-analyses of clinical trials as well as retrospective cohort studies suggest that high-
doses of traditional NSAIDS, including ibuprofen, indomethacin, and diclofenac, carry an 
increased risk similar to that of the COX-2 selective inhibitor celecoxib (134-136). 
Naproxen, a non-selective inhibitor of COX-1 and COX-2, is the outlier in these studies 
and appears to be of neutral risk and may convey a mild protective effect at high doses. 
As mentioned above, inhibition of TXA2 biosynthesis throughout the dosing interval, 
which is not observed with other commonly used NSAIDs, such as ibuprofen, may offset 
reductions in PGI2 or PGI2-G biosynthesis and contribute to the reduced cardiovascular 
adverse effects of the higher doses of naproxen (137). 
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Dissertation Aims 
The major goal of the research described herein was to provide further insight into 
the structural and functional determinants of COX inhibition by NSAIDs. A significant 
effort was made to identify the molecular basis for the activity of the non-selective 
NSAID, naproxen, because of its unique pharmacological properties and long history of 
human use.  An investigation of the kinetics of COX inhibition by naproxen and an 
analysis of the structure-activity relationship of naproxen are presented in Chapter II. As 
an extension of these studies, an in-depth mutagenesis study was performed, in which 
naproxen was tested against a library of COX-2 active site mutants to identify amino acid 
residues that are critical for naproxen binding. These results are discussed in Chapter III. 
Crystallographic analysis of the binding mode of naproxen within the active site of COX-
2 is also described in Chapter III. Together, these studies provide a comprehensive 
understanding of naproxen activity. Chapter IV will summarize my examination of the 
ability of NSAIDs to inhibit the oxygenation of the endocannabinoid, 2-AG, as compared 
to AA. The finding that weak inhibitors of AA metabolism are in some cases potent 
inhibitors of 2-AG oxygenation prompted the investigation of the activity of (R)-
enantiomers of 2-arylpropionic acids against endocannabinoids. These studies are 
presented in Chapter V.  Chapters IV and V together provide novel information regarding 
the molecular determinants for substrate-selective inhibition. In sum, the findings 
presented in Chapters II-V provide a greater understanding of COX structure and 
function as well as the actions of NSAIDS in vivo. Chapter VI will contain a brief 
discussion of the implications of this research. 
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CHAPTER II 
 
FUNCTIONAL ANALYSIS OF NAPROXEN ACTIVITY AGAINST 
CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 
 
 
Introduction 
Cyclooxygenases (COX-1 and COX-2) are bifunctional enzymes that catalyze the 
bis-dioxygenation of arachidonic acid (AA) to form the hydroxy endoperoxide, PGH2. 
PGH2 serves as the precursor to several biologically active prostanoids that are formed by 
the enzymatic activity of tissue specific synthases (1). The two COX isoforms have high 
sequence identity and similar three-dimensional structures, but differ in their expression 
profiles. COX-1 is constitutively expressed in most tissues and contributes predominantly 
to homeostatic prostaglandin biosynthesis. In contrast, COX-2 is inducibly expressed in 
most tissues in response to a broad range of physiological and pathophysiological stimuli. 
Recently, however, it has become evident that COX-2 is also constitutively expressed in 
the brain, kidney, and vascular systems, and that COX-1 plays a role in some 
inflammatory responses (2,3).  
The primary mechanism of the anti-inflammatory and antipyretic action of 
NSAIDs is inhibition of COX. Naproxen is one of the oldest and largest selling NSAIDs 
(Figure 1). It was introduced in prescription form as Naprosyn in 1976 and as the over-
the-counter drug, Aleve, in 1994 (4). It exhibits analgesic, anti-pyretic, and anti-
inflammatory activity and was recently reported to be effective in the prevention of 
bladder cancer progression even when administered several weeks after the tumor-
initiating agent (5). Naproxen is a non-selective NSAID that inhibits both COX-1 and 
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COX-2 with IC50 values in the low micromolar range for human recombinant enzymes 
(6). Inhibition of prostaglandin biosynthesis by naproxen has been confirmed in several 
human clinical studies (7,8). It exhibits significant gastrointestinal side effects, but recent 
mounting evidence suggests it does not exert cardiovascular side effects when 
administered in the higher doses that provide sustained inhibition of platelet COX-1 
throughout the dosing interval (e.g.> 500 mg twice daily) (7,9,10). This latter property 
has taken on increasing importance as evolving data suggest that the cardiovascular 
toxicity first exhibited by the COX-2-selective inhibitors rofecoxib and celecoxib extends 
to other selective or non-selective COX inhibitors including diclofenac, indomethacin, 
and ibuprofen (10-12). 
 The precise mechanism by which naproxen interacts with COX is still unknown. 
Therefore, we performed a functional analysis of naproxen activity against the COX 
enzymes by examining the kinetics of COX inhibition and the structure-activity 
relationship of naproxen. Our results suggest that, although there is a time-dependent 
component for inhibition of both COX-1 and COX-2 by naproxen, COX-1 is more 
sensitive to time-independent inhibition at low substrate concentrations. Further, the 
structure-activity analyses indicate that each of the pendant groups of the naphthyl 
scaffold is essential for COX inhibition, and only minimal substitutions are tolerated.  
 
Experimental Procedures 
Materials - (S)-Naproxen, 6-methoxy naphthalene acetic acid, and PGE2-d4 were 
purchased from Cayman Chemical Company (Ann Arbor, MI). 6-O-desmethyl naproxen 
and (R)–naproxen were purchased from Sigma-Aldrich (Milwaukee, WI). Arachidonic 
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acid (AA) for mass-spectrometry experiments was purchased from Nu-Check Prep, Inc.  
(Elysian, MN). [1-14C]-AA was purchased from PerkinElmer Life Sciences (Boston, 
MA) and diluted using 0.1 N NaOH.  Chemicals used for the synthesis of naproxen 
analogs were purchased from Sigma-Aldrich (Milwaukee, WI). The expression and 
purification of recombinant murine COX-2 (mCOX-2) and human COX-2  (hCOX-2) 
from SF-9 cells and the purification of ovine COX-1 (oCOX-1) from ram seminal 
vesicles were performed as previously described (13). 
 
Synthesis and characterization of naproxen analogs – Matthew Walters performed the 
synthesis of all naproxen analogs, and a detailed report of this chemistry has been 
published previously (14); a brief description is reported herein. A Methyl 2-(6-
methoxynaphthalen-2-yl)propanoic acid and 2-(6-methoxynapthalen-2-yl)-2-
methylpropanoic acid were synthesized as previously described by Stock et al. (15). To 
synthesize 2-(6-methoxynaphthalen-2-yl)butanoic acid, a Grignard reagent was formed 
with 2-bromo-6-methoxynapthalene, and this newly formed Grignard was then reacted 
with methyl 2-bromobutyrate. The resultant ester was subjected to hydrolysis under basic 
conditions to afford the desired acid.  
(2-(6-Ethylnapthalen-2-yl)propanoic acid and 2-(6-(methylthio)napthalen-2-
yl)propanoic acid were synthesized starting from the common intermediate (S)-methyl 2-
(6-(trifluoromethylsulfonyloxy)napthalen-2-yl)propanoate.  This intermediate was 
synthesized starting from (S)-naproxen, which was converted to des-methyl naproxen 
under acidic conditions (16), followed by methyl ester protection of the acid group (17) 
and trifiate protection of the phenolic oxygen.  For 2-(6-ethylnapthalen-2-yl)propanoic 
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acid, the triflic intermediate was coupled with potassium vinyltrifluoroborate using a 
Suzuki reaction, and the resulting alkene was reduced to the corresponding alkane 
followed by hydrolysis under basic conditions to afford the desired acid. 2-(6-
(Methylthio)napthalen-2-yl)propanoic acid was synthesized starting from the triflic 
intermediate, which was coupled to sodium triisopropylsilanethiolate (18), the resulting 
product was then deprotected using tetrabutylammonium fluoride followed by alkylation 
with iodomethane. The racemic acid was then obtained by basic hydrolysis.  The 
enantiomers were separated by chiral HPLC using either a Chiralpak AD or Chiralpak IC 
column, respectively. 
 2-(6-(Methylthio)napthalen-2-yl)propanoic acid was oxidized to form 2-(6-
(methylsulfinyl)naphthalen-2-yl)propanoic acid using chloroperoxybenzoic acid. 2-(6-
(Methylsulfonyl)naphthalen-2-yl)propanoic acid was formed by oxidation of 2-(6-
(methylthio)napthalen-2-yl)propanoic acid with oxone. The structures and their purity 
were confirmed by 1H-NMR and mass spectrometry. 
 
Time dependence of COX inhibition – To measure time independent inhibition, naproxen 
(1, 10, or 50 µM) and AA (1, 10, or 50 µM) were added simultaneously to hematin-
reconstituted enzyme (mCOX-2 = 50 nM, oCOX-1 = 25 nM) in 100 mM Tris-HCl buffer 
containing 500 µM phenol at 37 °C. For time-dependent inhibition, naproxen was 
allowed to incubate with the enzyme for 3 min at 37 °C before the addition of AA. The 
reactions were quenched after 8 s by the addition of an extraction solution of ethyl acetate 
containing 0.5% acetic acid and 1 µM PGE2-d4. To examine the effect of the length of 
pre-incubation time, naproxen and COX were incubated for periods varying from 0 to 3 
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minutes prior to reaction with AA. Following extraction, the organic layer was 
evaporated to near-dryness under nitrogen and reconstituted in 1:1 MeOH: H2O (v:v). 
Samples were chromatographed by liquid chromatography-mass spectrometry (LC-MS) 
using a Luna C18(2) column (50 × 2 mm, 3 µm) with an isocratic elution method (66:34 
(v:v), 5 mM ammonium acetate, pH 3.3: acetonitrile containing 10% A) at a flow rate of 
0.375 mL/min. Tandem mass-spectrometry (MS/MS) was conducted on a Quantum triple 
quadrupole mass spectrometer operated in positive ion mode. A mass transition of m/z = 
370 317 was monitored to measure the production of PGE2/D2 and m/z = 374 321 for 
PGE2-d4.  Peak areas for PGE2/D2 were normalized to PGE2-d4. Prostaglandin production 
for incubations containing inhibitor was normalized to the appropriate dimethyl sulfoxide 
(DMSO) control. 
 
Standard COX inhibition screening assay – Concentration-dependent inhibition reactions 
were performed by pre-incubating inhibitor and hematin-reconstituted enzyme in 100 
mM Tris-HCl buffer with 500 µM phenol for 17 min at room temperature followed by a 3 
min incubation at 37 °C. Following the addition of 50 µM [1-14C]-AA, samples were 
incubated for 30 s at 37 °C, and the reactions were then terminated by extraction with 
diethyl ether/methanol/citrate (30:4:1). The extracts were analyzed for substrate 
consumption by thin-layer chromatography (TLC) as previously described (19). All 
inhibitor concentrations for 50% enzyme activity (IC50) were determined by nonlinear 
regression analysis using Graphpad Prism software and were the average of at least two 
independent experiments. Inhibitors were prepared as stock solutions in DMSO, and 
diluted into reaction buffer so that the final DMSO concentration was 2.5%. Reactions 
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were run with hematin-reconstituted proteins at final enzyme concentrations adjusted to 
give approximately 30-35% substrate consumption (mCOX-2 = 154 nM, hCOX-2 = 94 
nM, oCOX-1 = 31.6 nM). AA was prepared as a stock solution in 0.1 N NaOH. For IC50 
determinations using 5 µM AA, the conditions were as described for the standard assay 
with a lowered enzyme concentration to allow for the appropriate amount of metabolism 
(oCOX-1 = 7.6 nM, mCOX-2 = 40 nM). 
 
COX inhibition assay for a substrate concentration of 500 nM – The COX inhibition 
assay described above was modified to perform IC50 determinations in the presence of 
sub-micromolar concentrations of AA (20). Hematin-reconstituted enzyme and inhibitor 
were incubated for 0 or 5 min at 37 °C before the addition of 0.5 µM [1-14C]-AA. The 
reaction was terminated after 8 sec, and substrate consumption was analyzed as described 
above. Enzyme concentrations were adjusted to allow approximately 30-50% substrate 
consumption under the modified conditions (mCOX-2 = ~20 nM, oCOX-1 = ~15 nM).  
 
Time course for product formation by COX- To examine the time course of product 
formation in the presence of inhibitor, 5 or 50 µM naproxen was incubated with enzyme 
(oCOX-1 = 31.6 nM, mCOX-2 = 154 nM) for 3 min at 37 °C. [1-14C]-AA was added at 5 
µM or 50 µM to naproxen-bound enzyme and allowed to react for 30 s, 1 min, 2 min, 3 
min, or 5 min to establish a time course for AA oxygenation. To measure reversibility at 
a low substrate concentration, hematin-reconstituted enzyme (oCOX-1 = 15 nM, mCOX-
2 = 20 nM) was incubated with 10 µM naproxen for 3 minutes prior to the addition of 1 
µM [1-14C]-AA. The reaction was allowed to proceed for 8, 15, 30, 45, 60, 90, 120, or 
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180 s.  Naproxen was prepared as a stock solution in DMSO as described above.  
Enzymes were reconstituted with approximately 2 molar equivalents of heme. The study 
was performed in 100 mM Tris-HCl buffer containing 500 µM phenol, pH 8.  Assays 
were terminated and analyzed for substrate consumption by TLC as described above. The 
amount of enzyme activity as compared to a DMSO control was plotted against the 
incubation times and fit to a single-exponential association with a plateau to determine 
kobs. The values reported were the average of two or more independent experiments. 
 
 
Results 
 
NSAIDs appear to follow a multistep kinetic mechanism for inhibition of COX 
enzymes (eq 1). Initial bimolecular association of the inhibitor with the enzyme is 
followed by a slower intramolecular step that results in a more tightly bound complex. In 
the case of aspirin, the intramolecular step results from acetylation of the active site 
residue, Ser-530, but in all other cases the inhibitor-enzyme association is non-covalent 
(21,22). The magnitude of the individual rate constants determines the apparent type of 
inhibition (eq 1).  
       (eq 1) 
 
Inhibitors with a very low k2/k-2 ratio appear to be rapid, reversible inhibitors, exhibiting 
kinetics consistent with simple competitive inhibition as k2/k-2 approaches zero.  In 
contrast, inhibitors with a significant k2/k-2 ratio exhibit time-dependent inhibition, often 
consistent with the behavior of slow, tight-binding inhibitors. If the k2/k-2 ratio is high, 
these inhibitors are functionally irreversible; however some NSAIDs that show time-
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dependent inhibition are reversible as revealed by the existence of a non-zero plateau for 
maximal inhibition. 
Gierse et al. reported that naproxen displays no time-dependence for inhibition of 
COX-1 and “mixed” inhibition for COX-2. “Mixed” inhibition in this context was 
characterized by an initial time-dependent loss of enzyme activity followed by a non-zero 
plateau (23). This type of inhibition is characteristic of a weakly binding, readily 
reversible inhibitor. We explored the time-dependence of COX inhibition by naproxen 
using a very low concentration of AA (500 nM; ~ 0.1 Km). In the absence of a 
preincubation, the IC50 value for naproxen inhibition of oCOX-1 was approximately 5.6 
µM, and nearly 100% inhibition was achieved at 25 µM inhibitor (Figure 1A). For 
mCOX-2, the extent of inhibition was very low so that an IC50 value could not be 
determined at concentrations of up to 25 µM naproxen (Figure 1B). Following a three-
min incubation of COX and naproxen prior to the addition of AA, we observed 
substantial concentration-dependent inhibition of AA turnover for both COX isoforms. 
Naproxen inhibited oCOX-1 with an IC50 value of 340 nM and mCOX-2 with an IC50 
value of 180 nM and demonstrated greater than 80% inhibition of both isoforms in the 
presence of 500 nM AA (Figure 1). These data suggest the existence of a significant 
time-dependent component of naproxen inhibition for both COX-1 and COX-2. This 
time-dependence was observed with higher concentrations of AA as well (1, 10, and 50 
µM – Figure 2).  
In an attempt to determine the kinetic constants for time-dependent inhibition, 
naproxen was preincubated with COX-2 for varying lengths of time before the addition 
of 50 µM AA. As shown in Figure 3, maximal inhibition was reached within eight  
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Figure 1. Effect of pre-incubation of enzyme and inhibitor on COX inhibition by 
naproxen. Closed circles () represent incubations in which naproxen  (0.05 – 25 µM) 
and AA (500 nM) were added simultaneously to COX. For the incubations represented 
by open circles (), COX was pre-incubated with naproxen (0.05-4 µM) for 5 minutes 
before the addition of 500 nM AA. Panel A is representative of incubations with oCOX-1 
and Panel B represents reactions with mCOX-2. The reaction with substrate was allowed 
to proceed for 8 seconds before quenching. Substrate consumption was analyzed by TLC 
as described in Experimental Procedures to determine approximate IC50 values. Each data 
point is the mean of at least two experiments in duplicate. 
 
 
 
Figure 2. Kinetic basis of COX by naproxen. Upper panels: DMSO or 1, 10, or 50 µM 
naproxen and 1, 10, or 50 µM AA were added simultaneously to hematin-reconstitued 
oCOX-1 (A) or mCOX-2 (B) and allowed to react for 8 sec. Lower Panels: DMSO or 
naproxen was incubated with enzyme (C - oCOX-1, D - mCOX-2) for 3 min at 37 °C 
prior to the addition of 500 nM AA for 8 sec. PG production was measured by 
LC/MS/MS as described under “Experimental Procedures”. 
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Figure 3. Effect of pre-incubation time on the inhibition of COX-2 by naproxen. 
Naproxen (10 or 50 µM) was pre-incubated with COX-2 for 0, 5, 8, 15, 30, 45, 60, or 120 
seconds prior to the addition of AA for 30 seconds. Reactions were terminated with 
organic solvent containing PGE2-d4, and prostaglandin production was measured by 
tandem-mass spectrometry as described in Experimental Procedures.  
 
 
seconds so that kinetic parameters could not be determined.  Similar results were 
obtained with COX-1. 
In subsequent studies, we utilized an IC50 assay designed for time-dependent 
inhibitors to elucidate tight-binding interactions critical for the formation of the 
naproxen-mCOX-2 complex. Under our standard assay conditions, enzyme and inhibitor 
were preincubated for 20 min prior to the addition of a saturating concentration of 
substrate (50 µM) for 30 sec. In this assay, the inhibition of oCOX-1 activity reached a 
plateau at approximately 50% inhibition and an IC50 value could not be determined at 
concentrations up to 25 µM. Naproxen appeared to be a slightly more potent inhibitor of 
mCOX-2 in that an IC50 value of 0.90 µM (~70% inhibition) could be measured (Figure 
4). An inhibition assay was performed using hCOX-2 (data not shown), and the IC50 was 
determined to be 0.75 µM with an inhibition curve that plateaued at approximately 55%. 
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Figure 4. COX inhibition by naproxen. Naproxen was screened in a standard time-
dependent IC50 screen against wt mCOX-2 () and oCOX-1 (). Naproxen (0.25 – 25 
µM) was pre-incubated with the enzyme for 20 min prior to the addition of substrate (50 
µM) for 30s at 37 °C as described under “Experimental Procedures.” Each point 
represents the average of two or more independent determinations. 
 
 
The inhibition curves shown in Figure 4 reach a non-zero plateau value, which is 
consistent with a time-dependent, reversible inhibitor (23). To investigate this apparent 
residual activity in greater detail, the time course of product formation in the presence of 
maximally inhibiting naproxen concentrations and saturating AA was obtained. Naproxen 
(5 or 50 µM) was prebound to purified enzymes for 3 min at 37 °C, followed by the 
addition of AA at a concentration of 50 µM. The reaction was allowed to progress for 
various times up to five minutes, and the extent of conversion of AA to prostaglandins 
was determined. The amount of product formation was plotted against the incubation 
time and fit to the equation Y = Vo/kobs(1-exp(kobs∗t))  (R2 = .95 - .99), where Vo is the 
initial reaction velocity and kobs is the first order rate constant for the change in reaction 
rate. COX enzymes undergo a first order self-inactivation, which is the primary 
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contributor to kobs. However, in the presence of a prebound reversible inhibitor, 
increasing reaction times should lead to a decrease in the extent of inhibition and an 
increasing reaction rate, which counteracts the self-inactivation.  Enzyme inhibition can 
also directly slow the rate of self-inactivation by slowing the generation of inactivating 
species. Consequently, the kobs values obtained are likely the result of a combination of 
multiple factors.  
Figure 5. Time course for product formation in the presence of naproxen. In panels 
A & D, DMSO (), 5 () or 50 () µM naproxen was preincubated with oCOX-1 (A) or 
mCOX-2 (D) for 3 minutes before the addition of 50 µM AA. The reaction was allowed 
to proceed for 30, 45, 60, 120, 180, or 300 sec. Panels B (oCOX-1) & E (mCOX-2) are 
representative of experiments identical to panels A & D with addition of 10 µM AA. In 
panels C & F, 1 µM AA was added to 5 () or 10 () µM naproxen (or DMSO ()) 
prebound to oCOX-1 (C) or mCOX-2 (F) for 8,15,30,60,90,120,180 or 300 s. Substrate 
consumption was analyzed as described. 
 
Table I summarizes values for initial velocity and maximal product (Vo/kobs) 
formed in the presence and absence of inhibitor.  Although the inhibitor consistently 
reduced the initial velocity of the reaction in a concentration-dependent manner, the time 
course of the reaction was prolonged in the presence of naproxen, as shown in Figure 5.   
In the case of COX-2, this effect actually led to greater levels of total product in the 
presence of the inhibitor than in its absence, while the total levels of product formed by  
A B C 
D E F 
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Table I. Initial velocity and maximal product formation by COX in the presence and 
absence of naproxen. 
COX-1     
 DMSO 5 µM naproxen 10 µM naproxen 50 µM naproxen 
1 µM AA     
Vo 0.026 n.a. n.a. n.d. 
plateau 0.670 no plateau no plateau n.d. 
10 µM AA     
Vo 0.710 0.210 n.d. 0.049 
plateau 7.900 7.900 n.d. 5.500 
50 µM AA     
Vo 1.700 1.200 n.d. 0.620 
plateau 38.00 40.00 n.d. 37.00 
COX-2     
 DMSO 5 µM naproxen 10 µM naproxen 50 µM naproxen 
1 µM AA     
Vo 0.032 0.011 0.0054 n.d. 
plateau 0.830 0.730 0.560 n.d. 
10 µM AA     
Vo 0.470 0.120 n.d. 0.071 
plateau 8.200 8.000 n.d. 7.000 
50 µM AA     
Vo 0.690 0.290 n.d. 0.270 
plateau 23.00 25.00 n.d. 28.00 
     
Methods described in Figure 5. Vo is expressed in µM/sec and the quantity of maximum 
products, or plateau, in µM. n.d. indicates a value was not determined.  
 
COX-1 in the presence of naproxen approached, but did not exceed, those of control 
samples. The results of experiments in which 10  µM AA was used were similar to those 
conducted using 50 µM AA, in that the initial velocity was significantly lower and the 
reaction proceeded for a longer period time in the presence of both 5 and 50 µM 
naproxen compared to uninhibited enzyme. At this substrate concentration, the total 
amount of products only reached those of control samples at 5 µM naproxen for both 
COX-1 and COX-2 in the allotted time. We also attempted these experiments at a 
substrate concentration of 1 µM, which is near that of the Km for COX. Here, no plateau 
was reached for reactions involving COX-1, and total product formation in the presence 
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of 5 µM naproxen was less than 30% of uninhibited enzyme after a five-minute 
incubation with substrate; at 10 µM naproxen, product formation was essentially 
undetectable. In contrast, we were able to observe significant product formation under 
thesame conditions for COX-2. Together, these results highlight the importance of assay 
conditions in measuring inhibitory activity of NSAIDs, as the amount of observable 
inhibition is highly dependent upon the allowed reaction time, particularly at high 
substrate concentrations, and as such comparing IC50 values determined using different 
assays is difficult. The results also suggest that slowing of enzyme self-inactivation in the 
presence of inhibitor can lead to greater total product formation than would be expected 
from measurements of initial velocity alone.  
 
Structure-activity analysis. In addition to examining the kinetics of COX inhibition, we 
sought to elucidate structure-activity relationships for naproxen. Early structure-activity 
studies were conducted before the identification of the COX enzymes as the molecular 
targets for non-steroidal anti-inflammatory drugs. These studies indicated that the 
carboxylate group of naproxen was required for activity. We confirmed the importance of 
this moiety by synthesizing a naproxen methyl ester analog and found that it was unable 
to inhibit either COX isoform at concentrations up to 25 µM.  
 The early studies conducted by Harrison et al. also indicated that the presence 
of an a-methyl group improved potency in animal models of pain and inflammation (24). 
To determine whether the α-methyl group was an important determinant of the 
interaction between naproxen and COX, 2-des-methylnaproxen was assayed against WT 
COX-1 and COX-2. Elimination of the methyl group resulted in a significant decrease in 
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inhibition of WT COX-1 and COX-2 (maximum inhibition 10-20% at concentrations up 
to 25 µM) (Table II). The addition of extra steric bulk at the α-position also resulted in a 
loss of potency, as the α-ethyl analog of naproxen displayed no inhibition of either wild-
type COX-1 or COX-2 enzymes in our standard IC50 assay (Table II). Similarly, bulkier 
substitutions at the α-position of another 2-arylpropionic acid, flurbiprofen, result in a 
complete loss of inhibition of COX-1 (25). Thus, the (S)-α-methyl group is a critical 
determinant of naproxen efficacy, and it cannot be replaced with smaller (hydrogen) or 
larger (ethyl) substituents.  
 The majority of NSAIDs of the 2-arylpropionic acid family are marketed as 
racemic mixtures, but naproxen is sold exclusively as the (S)-enantiomer. The (S)-
enantiomer is significantly more potent than the (R)-enantiomer in inflammatory models 
in vivo, which is typical of members of the 2-arylpropionic acid class of inhibitors (24).  
In the presence of saturating substrate concentrations, the (R)-enantiomer did not inhibit 
oCOX-1 or mCOX-2 to any appreciable extent at concentrations up to 25 µM (Table II). 
Previous studies suggest that the strict stereoselectivity of the 2-arylpropionic acid class 
of inhibitors is due to unfavorable steric interactions with Tyr-355 when the methyl group 
of the inhibitor is in the (R)-stereochemistry (26) (27,28). However, the lack of inhibition 
observed with the des-methyl naproxen analog raised the possibility that the inability of 
the (R)-enantiomer to inhibit is due to the absence of the (S)-methyl group. To address 
this possibility, the α,α-dimethyl analog was synthesized and tested for its ability to 
inhibit mCOX-2 (29).  Assuming that this compound occupies the active site in a manner 
analogous to naproxen, the (S)-methyl group should be in position to interact with the  
 
	   77	  
TABLE II. Determination of IC50 values of naproxen analogs with WT COX  
Analog COX-1 COX-2 
 
>25 µM (50%) 0.9 µM (70%) 
 
>25 µM (20%) >25 µM (10%) 
 
 
>25 µM (10%) >25 µM (20%) 
 
no inhib. >25 µM (10%) 
 
no inhib. no inhib. 
 
>25 µM (20%) >25 µM (10%) 
 
>25 µM (30%) >25 µM (30%) 
 
>25 µM (10%) >25 µM (25%) 
 
14 µM (50%) 
 
12.5 µM (50%) 
 
 
>25 µM (30%) 
 
20 µM (60%) 
 
Each naproxen analog was assayed against purified oCOX-1 and mCOX-2 as described 
under Experimental Procedures for standard COX inhibition assays (50 µM AA). “No 
inhib” indicates less than 10% inhibition up to inhibitor concentrations of 25 µM. The 
number in parentheses represents the extent of inhibition indicating where the plateau for 
inhibition is reached for each inhibitor. 
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 pocket below Val-349 in the COX active site. However, the α,α-dimethyl analog was 
completely inactive against oCOX-1 or mCOX-2 (Table I). This is consistent with 
previous reports demonstrating that a dimethyl substitution for the α-methyl group of 
flurbiprofen eliminates COX-1 inhibition (25). While the presence of an (R)-methyl 
substituent clearly eliminates inhibition, the (S)-methyl group makes key interactions 
within the COX active site that are essential for binding and inhibition. 
 To probe the importance of the p-methoxy group, we synthesized a series of 
analogs with different substituents in the para position.  The p-hydroxy analog (O-
desmethyl naproxen), which is the major in vivo metabolite of naproxen, was a very weak 
inhibitor, exhibiting roughly 30% inhibition up to 25 µM (Table II) (30). Further, the o-
ethoxy analog was completely inactive against both COX-1 and COX-2, indicating that 
changes in size at this position are not tolerated (Table II). To further investigate potential 
interactions between the p-methoxy moiety of naproxen and surrounding COX residues, 
we synthesized two naproxen analogs, in which an ethyl or methylthio group was 
substituted for p-methoxy to introduce variations in size and polarity as well as eliminate 
the possibility of hydrogen-bonding interactions. The methylthio analog has been 
reported to exhibit anti-inflammatory activity in vivo but has not been tested in vitro. The 
ethyl analog has not been reported. Both the p-ethyl and p-methylthio analogs were able 
to inhibit wild-type mCOX-2 to the same extent as naproxen (IC50 = 0.67 µM and 0.77 
µM in the presence of 50 µM AA) (Table II). Interestingly, both analogs exhibited a loss 
of potency compared to naproxen when tested against oCOX-1 so that no IC50 value 
could be determined at inhibitor concentrations up to 25 µM (Table II). We also observed 
an increase in COX-2 selectivity at reduced substrate concentrations (500 nM and 5 µM  
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Table III: IC50 values for the inhibition of WT COX by naproxen and naproxen 
analogs in the presence of varying substrate concentrations.  
 Analog COX-1 COX-2 
 
>25 µM (50%) 0.9 µM (70%) 
 
>25 µM (45%) 0.67 µM (65%) 50 µM AA 
 
>25 µM (40%) 0.77 µM (70%) 
 
200 nM (70%) 610 nM (80%) 
 
 
2.6 µM (50%) 270 nM (80%) 5 µM AA 
 
1.0 µM (70%) 450 nM (70%) 
 
230 nM (75%) 53 nM (90%) 
 
 
880 nM (75%) 72 nM (90%) 
 
 
570 nM (75%) 63 nM (95%) 
Naproxen and the naproxen analogs were screened against purified oCOX-1 and mCOX-
2 as described under Experimental Procedures for 50 µM, 5 µM, and 0.5 µM substrate 
concentrations. Reactions were quenched with an extraction solution of ethyl acetate 
containing 0.5% acetic acid (v/v) and 1 µM PGE2-d4. PGE2/D2 production was analyzed 
by LC-MS/MS as described under Experimental Procedures. Numbers in parenthesis 
represent the extent of inhibition.  
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AA) (Table III). As an extension of these studies, we tested the ability of naproxen 
derivates with p-methylsulfinyl and p-methylsulfonyl substitutents to inhibit the COX 
enzymes and found that both analogs appeared to be weak, nonselective inhibitors of both 
isoforms (Table II). The IC50 values for the p-methylsulfinyl naproxen derivative against 
COX-1 and COX-2 were approximately 14 µM and 12 µM (approximately 50% 
inhibition), respectively. No IC50 value could be determined for the p-methylsulfonyl 
analog when tested against COX-1, and the IC50 value for COX-2 was approximately 20 
µM. Taken together, the results with these analogs suggest important and specific 
interactions between the p-methoxy group and COX active site residues.  
 
Discussion 
 
Naproxen has been an FDA-approved drug since the mid-1970s, but there are few 
literature reports regarding its precise mechanism of action. Previous kinetic studies 
indicated that naproxen exhibits time-dependent “mixed” inhibition for COX-2 and no 
time dependence for COX-1 as measured by loss of arachidonate-driven peroxidase 
activity (23). Consistent with these studies, our analyses indicate that, while COX-1 is 
more sensitive to time-independent inhibition, there is a time-dependent component for 
inhibition of both COX isoforms by naproxen (Figures 1 and 2). We observed a rapid 
dissociation of preformed COX-naproxen complexes as determined by the time course of 
oxygenation of AA when added at saturating concentrations (Figure 4). The kobs value for 
AA oxygenation by mCOX-2 in the presence of naproxen remains relatively constant 
regardless of substrate concentration. In the presence of saturating concentrations of 
substrate, the dissociation rate of naproxen from oCOX-1 is slightly higher than mCOX-
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2. However, the rate of reversibility for naproxen appears to be significantly slower for 
COX-1 compared to COX-2 at 1 µM AA. The results at low substrate concentrations may  
partially explain why a more complete inhibition of thromboxane synthesis (COX-1-
mediated) as compared to prostacyclin synthesis (COX-2-mediated) is observed in 
humans (7,31). 
Naproxen is a relatively simple molecule with only three functional groups 
distributed on opposite ends of the naphthyl scaffold. Our data indicate that each of these 
substituents is required for potent inhibition of both COX isoforms and that very little 
structural variation is tolerated. Early SAR studies concluded that three structural 
components were crucial for the activity of naproxen: an acidic group at position 1, an 
aromatic system, and a small lipophilic group at position 6 (6). Additionally, introduction 
of a methyl group in the alpha position further increased anti-inflammatory activity. 
These studies were conducted using animal models, as the target of naproxen had not yet 
been identified. Since the discovery of COX enzymes, no further work has been 
conducted to examine the molecular interaction between naproxen and COX, and as such, 
it was unclear what naproxen moieties are key for inhibition of the individual COX 
enzymes. Therefore, we performed a structure-activity analysis to investigate the 
importance of each functional group in the inhibition of COX-1 compared to COX-2.  
As previous studies suggested, the carboxylic acid appears to be critical for the 
binding as evidenced by the minimal inhibitory activity of a methyl ester naproxen 
analog. The α-methyl group of naproxen also appears to be involved in critical 
interactions with the COX enzymes. Introduction of a range of substituents of varying 
size and stereochemistry at the α-position suggests the steric requirements for this 
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interaction are stringent while removal of the α-methyl group also results in a dramatic 
loss of potency (Table II). The region of the enzyme that interacts with the p-methoxy 
moiety of naproxen appears to be strict in its ability to bind functional groups; the p-
hydroxy and p-ethoxy analogs were very weak inhibitors whereas a methylene or sulfur 
substitution for the oxygen atom of the p-methoxy group of naproxen generated potent 
inhibitors of WT mCOX-2. Further, the p-methylsulfinyl and p-methylsulfonyl naproxen 
derivatives were significantly less potent than the p-methylthio analog and naproxen 
itself.  
It is clear that there is great diversity and subtlety in the types of molecular 
interactions that result in COX inhibition and selectivity for isoforms. Even viewed from 
this perspective, our discoveries of the effect of methylene and sulfur substitution for the 
oxygen atom of the p-methoxy group of naproxen seem extraordinary, in that a single 
atom substitution increases their COX-2-selectivity. Together with the evidence that 
naproxen exhibits unique kinetics of inhibition for each of the COX enzymes, these data 
suggest that naproxen adopts a unique binding conformation within each of the COX 
active sites. This hypothesis is supported by the finding that naproxen is unable to inhibit 
a mutant hCOX-2 enzyme in which Val-523 has been replaced by the corresponding 
COX-1 residue, Ile, despite being an effective inhibitor of both COX-1 and COX-2 (32). 
The distinct binding modes may arise from the difference in size between the COX-1 and 
COX-2 active sites, as the COX-2 site is approximately 20-30% larger, combined with 
the inflexibility of naproxen due to the rigid naphthyl backbone. The elucidation of the 
critical interactions between naproxen and mCOX-2 can be used in the specific design of 
more potent or selective naproxen analogs. In the future, a truly COX-2-selective 
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naproxen analog may be used as a tool to determine whether or not increased 
cardiovascular risk is linked to isoform selectivity. 
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CHAPTER III 
 
AMINO ACID DETERMINANTS OF CYCLOOXGYENASE INHIBITION BY THE 
NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUG, 
NAPROXEN 
 
 
Introduction 
 
 Cyclooxygenase (COX) enzymes are the targets for inhibition by a diverse array 
of non-steroidal anti-inflammatory drugs (NSAIDs) that contain functional groups such 
as arylacetic acids, arylpropionic acids, β-ketoenols, and diarylheterocycles. Investigation 
of the molecular determinants of inhibition by different classes of compounds reveals that 
the protein residues in the active site maintain similar orientations and that each chemical 
class forms distinct sets of interactions within the active site (1). Compounds with 
nanomolar binding affinity – and in many cases, COX-2 selectivity – have been 
successfully designed for multiple chemical series, in spite of their diverse binding 
modes. 
COX-1 and COX-2 are functional homodimers, and each monomer consists of 
three major structural domains: the epidermal growth factor domain located at the N-
terminus, a membrane binding domain, and a large globular catalytic domain containing 
the cyclooxygenase and peroxidase active sites (2,3). The cyclooxygenase and peroxidase 
sites are structurally distinct but mechanistically coupled. Substrate and inhibitors travel 
through the membrane-binding domain at a site termed the “lobby” to enter the 
cyclooxgenase active site. The COX active site is separated from the lobby by a 
constriction composed of three residues: Arg-120, Tyr-355, and Glu-524. While the 
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COX-1 and COX-2 active sites are very similar, the COX-2 active site is approximately 
20-30% larger than that of COX-1; the size difference is partially attributed to a single 
amino acid change (Ile-523 in COX-1, Val in COX-2) which limits stable binding in a 
pocket of the main cyclooxygenase active site (4).  
Naproxen is a widely used over-the-counter NSAID with analgesic and 
antipyretic properties. Despite the fact that it has been marketed for many years, 
relatively little is known of the structural determinants of naproxen’s interaction with the 
COX enzymes. No crystal structures have been reported for naproxen bound to COX-1 or 
COX-2 and relatively little information has been reported on the amino acid determinants 
of naproxen interaction with the COX active sites (5). Considering its continuing 
importance in the treatment of a range of inflammatory disorders and its intriguing side 
effect profile, we conducted an investigation of naproxen-COX interactions using site-
directed mutagenesis and X-ray crystallography. The results reveal a novel molecular 
determinant of COX binding not seen with other NSAIDs. 
 
Experimental Procedures 
Materials - (S)-Naproxen was purchased from Cayman Chemical Company (Ann Arbor, 
MI). Reagents used in the synthesis of naproxen analogs were purchased from Sigma-
Aldrich (Milwaukee, WI). Synthetic procedures are described in Chapter II.  [1-14C]-
Arachidonic acid (AA) was purchased from PerkinElmer Life Sciences (Boston, MA) 
and diluted using 0.1 N NaOH. Crystallography reagents were purchased from Hampton 
Research (Aliso Viejo, CA). 
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Enzymes –The expression and purification of recombinant murine COX-2 (mCOX-2), 
and site-directed mutagenesis to generate various active site mutants (V349A, V349I, 
V349L, R120A, R120Q, Y355F, W387F) was performed according to published methods 
(6-8). The specific activities of W387F mCOX-2 and R120Q mCOX-2 were 2.1 and 23.9 
µM AA per µM enzyme per min, respectively (compared to 13.7 for WT mCOX-2); the 
specific activities of all other mutant enzymes have been reported previously (7,8). 
 
Standard COX inhibition screening assay – Hematin-reconstituted enzyme and inhibitor 
were pre-incubated for 17 min at room temperature then 3 min at 37 °C prior to addition 
of 50 µM [1-14C]-AA for 30 sec at 37 °C. The reactions were terminated by extraction 
with diethyl ether/methanol/1 M sodium citrate (30:4:1, v:v:v) and analyzed for substrate 
consumption by thin-layer chromatography as previously reported (9). Reactions were 
run with hematin-reconstituted proteins at final enzyme concentrations adjusted to give 
approximately 30-35% substrate consumption (mCOX-2 = 154 nM, hCOX-2 = 94 nM, 
oCOX-1 = 31.6 nM, V349A = 250 nM, V349I = 268 nM, V349L = 113 nM, R120A = 
100 nM, R120Q = 159 nM, Y355F = 174 nM, W387F = ~750 nM, V523I = 83 nM). AA 
was prepared as a stock solution in 0.1 N NaOH, and inhibitors were prepared as stock 
solutions in dimethyl sulfoxide (DMSO). IC50 values (inhibitor concentrations for 50% 
enzyme activity) were determined by nonlinear regression analysis and are the average of 
multiple determinations of duplicate analyses. 
 
COX-2 crystallization – Murine recombinant COX-2 was purified from Sf21 insect cells 
as previously described (10). Following the initial anion-exchange and gel filtration 
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columns, anion-exchange chromatography was repeated on an 8 mL Mono-Q column 
followed by size-exclusion chromatography using the same conditions as the first two 
columns. mCOX-2 was stored at -80 °C at 1-2 mg/mL for further use. For crystallization, 
protein was concentrated to approximately 10 mg/mL and reconstituted with 1 eq. of 
heme from a 15 mM stock in DMSO. Hematin-reconstituted mCOX-2 was dialyzed 
overnight at 4 °C in exchange buffer containing 100 mM NaCl, 20 mM Na3PO4, pH 6.7, 
0.6% beta-octyl glucoside (β-OG), and 0.01% NaN3. Inhibitor complexes were formed 
by the addition of 1 mM inhibitor from a 50 mM stock in ethanol for 15-20 min on ice 
immediately before setting up hanging-drop crystallization trays. mCOX-2 crystals were 
grown as previously described with the following alterations to the procedure (11).  The 
crystallizations were conducted in darkness, and crystals were transferred into a 
cryosolution of a diffusion-equilibrated sitting drop containing a 1:1 ratio of COX-2 
inhibitor complex and well solution (28% polyethylene glycol monomethyl ether 550, 
100 mM MgCl2, 50 mM N-[Hydroxyethyl]piperazine-N’-[3-propane-sulfonic acid] 
(EPPS), pH 8.0) that was set up at the time of the initial crystallization. 
Crystals were flash frozen and data were collected at the Southeastern Regional 
Collaborative Access Team (SER-CAT) beam line 22-ID or the Life Sciences 
Collaborative Access Team (LS-CAT) beam line 21-ID-F at the Advanced Photon 
Source at Argonne National Laboratory. The mCOX-2:naproxen co-crystal belongs to 
space group I222 with unit cell dimensions a=122.3 Å, b=133.2 Å, c=181.3 Å, and α = β 
= γ = 90°. The crystal diffracted X-rays to a 1.7 Å resolution. There was a single mCOX-
2 dimer in the asymmetric unit. The mCOX-2:p-methylthio naproxen crystal belongs to 
space group P21212 with unit cell parameters a=181.2 Å, b=134.2 Å, c=122.0 Å, and α = 
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β = γ = 90°. The asymmetric unit consisted of two mCOX-2 dimers; inhibitor was bound 
in each monomer. The structures were determined by molecular replacement using a 
Pfizer high resolution structure as the search model and the program MOLREP (12).  
Data collection and refinement statistics can be found in Table I. The models were 
refined using REFMAC5 (13) with iterated manual fitting using COOT (14). The 
coordinates and structure factors have been deposited in the Protein Data Bank under 
accession codes: 3NT1 for naproxen and 3NTB for the naproxen analog.   
 
Results 
Arylcarboxylic acid inhibitors bind in one of two orientations in the COX active 
site (Figure 1). Flurbiprofen binds in the canonical fashion with its carboxylate moiety 
ion-paired and hydrogen-bonded to the constriction site residues Arg-120 and Tyr-355 
(Figure 1B) (2,11). In contrast, diclofenac binds in an inverted orientation in which its 
carboxylate is hydrogen bonded to the sidechains of Tyr-385 and Ser-530 (Figure 1C) 
(7). These two orientations can be discriminated by mutations of constriction site 
residues, which abolish inhibition by flurbiprofen but have no effect on inhibition by 
diclofenac. Mutation of Tyr-355 to Phe in mCOX-2 abolished inhibition by naproxen 
(Figure 2A); whereas, mutation of Arg-120 to Gln slightly increased the potency of 
inhibition as compared to WT as exhibited by an improved IC50 and a greater extent of 
inhibition (~90%). Mutation of Arg-120 to Ala resulted in a complete loss of enzyme 
inhibition by naproxen (Figure 2A). Together, these results imply that the carboxylate 
group of naproxen binds at the constriction site in the canonical orientation, coordinated 
to Tyr-355 and Arg-120.  
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Figure 1. Chemical structures of NSAIDs and crystal structures of flurbiprofen and 
diclofenac bound in mCOX-2 active site. A. Chemical structures of naproxen, 
flurbiprofen, diclofenac, and indomethacin. B. The structure of flurbiprofen (3PGH, 
inhibitor carbon atoms colored gold) and C. diclofenac (1PXX) bound at the COX-2 
active site show the opposing binding modes that position their acidic groups either 
coordinated to the constriction residues Arg-120 and Tyr-355 at the base of the active site 
or to the catalytic Tyr-385 as well as Ser-530 at the top of the pocket. 
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Figure 2. Inhibition of mCOX-2 active site mutants by naproxen and nonselective 
NSAIDs. A. Naproxen (0.25 – 25 µM) was pre-incubated with WT mCOX-2 () or 
R120A (), R120Q () and Y355F () mCOX-2 mutant enzymes for 20 min prior to 
the addition of substrate (50 µM) for 30s at 37 °C. B. Naproxen (), indomethacin (), 
diclofenac () or flurbiprofen () was preincubated with mCOX-2 W387F for 20 min 
prior to the addition of substrate (50 µM). Inhibitor concentrations ranged from 0.25 – 25 
µM. Data were fit to a one-phase decay model to determine approximate IC50 values. 
Data points represent the mean of duplicate determinations. Data points for naproxen 
against W387F represent the mean of five independent experiments in duplicate. 
 
In order to rigorously examine the binding mode predicted from these studies, we 
determined the co-crystal structure of naproxen bound to mCOX-2 at 1.7 Å resolution, 
the highest resolution COX structure to date and among the highest resolution membrane 
protein structures described. The topology of the COX dimer and active site resemble 
those of previous studies, though we have resolved additional solvent, ion, and detergent 
molecules not observed in lower resolution structures.  Somewhat surprisingly, the 
residues lining the active site were observed in single conformations, despite the fact that 
many of them were bordered only by solvent.  The resolution of this structure enabled the 
identification of a β-OG molecule lying on the external side of the constriction, at the 
base of the funnel-shaped entrance to the active site (lobby region).  Similar observations 
were reported for high resolution structures of COX-1 (e.g., 2AYL) (15).  A solvent 
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molecule is often observed hydrogen bonded to Tyr385 and Ser 530 in the active site; 
however, when this density was fitted with a water molecule in the current structure, a 5σ 
residual electron density peak remained at that position.  When fitted with a chlorine 
atom, the residual peak disappeared, and the atom refined to a temperature factor similar 
to neighboring protein and inhibitor atoms. A peak in the anomalous difference map at 
the same location provided further evidence that the peak was a chlorine atom. While the 
physiological significance of chloride binding at this position is unknown, chloride ions 
have been used previously to identify the binding site of molecular oxygen in various 
proteins including dioxygenases (16,17). This raises the possibility that the chloride ion 
may be indicative of the position of molecular oxygen prior to incorporation into COX 
substrates.  
Strong electron density was observed for a single orientation of naproxen binding 
within the COX-2 active site, making no contacts in the COX-2 side pocket or lobby 
region (Figure 3). As predicted by the mutagenesis data, the binding mode of naproxen is 
similar to that of other members of the 2-arylpropionic acid family of NSAIDs with the 
carboxylate group of naproxen participating in hydrogen-bonding interactions with Arg-
120 (2.8 Å and 2.9 Å) and Tyr-355 (2.5 Å) at the base of the active site. The remainder of 
the interactions between the compound and protein were van der Waals contacts.  The 
(S)-α-methyl group of naproxen inserts into the hydrophobic cleft adjacent to Val-349 
while the naphthyl backbone of naproxen makes hydrophobic contacts with Ala-527,  
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Table 1. X-ray data collection and refinement statistics 
Data set naproxen p-methylthio naproxen 
Beamline LS-CAT APS 21 ID-F SER-CAT APS 22 ID  
Wavelength 0.97856 1.0000 
Space group I222 P21212 
Unit cell dimensions a=122.3Å, b=133.2Å, 
c=181.3Å, a=b=g=90° 
a=181.2Å, b=134.2Å, 
c=122.0Å, a=b=g=90° 
# molecules / ASU 2 4 
Resolution (all, highest bin) 35.0-1.73Å, 1.79-1.73Å 20.0-2.27Å, -2.35-2.27Å 
R-factor (all, highest bin) 6.7%, 40.9% 12.4%, 50.9% 
I/sI (all, highest bin) 23.3, 2.0 12.2, 2.0 
Completeness (all, highest bin) 98.6%, 97.8% 97.8%, 91.9% 
Redundancy 4.6 4.9 
   
Refinement   
Resolution (all, highest bin) 30.0 – 1.73Å 19.9-2.27Å 
# reflections 142,975 131,041 
R-factor 16.7% 23.4% 
Rfree 18.6% 26.3% 
Rmsd ideal values   
     Bond lengths 0.006Å 0.006Å 
     Bond angles 1.063° 0.895° 
B-factors   
     Protein 26.5 Å2 50.1 Å2 
     Ligand 22.1 Å2 42.3 Å2 
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Figure 3. Crystal structure of naproxen bound to mCOX-2. A. Difference electron 
density map (FO-FC) contoured at 3.5σ of the COX-2 active site prior to the addition of 
naproxen to the model or modification of sidechain positions in the binding pocket.  This 
and other molecular graphics images were composed with PyMol (Delano Scientific). B. 
Stereoview of the crystal structure of naproxen (blue carbon atoms) bound at the COX-2 
active site reveals that it forms extensive van der Waals contacts within the binding 
pocket and hydrogen bonds, similar to flurbiprofen, to the sidechains of Tyr 355 and Arg 
120.  The inhibitor does not enter the side pocket into which the phenyl sulfonamide or 
phenyl sulfone moieties of diaryl heterocyclic compounds protrude. 
 
Figure 4
A
B
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Gly-526 and Leu-352. Interestingly, the side chain of Leu-352 adopts an alternate 
conformation from that observed in the co-crystal structures of flurbiprofen, 
indomethacin, and diclofenac bound to mCOX-2.  The p-methoxy group of naproxen is 
oriented towards the apex of the COX active site and forms van der Waals interactions 
with Trp-387 and Tyr-385. 
 The mCOX-2:naproxen crystal structure indicates that the (S)-α-methyl group of 
naproxen is oriented in a conformation similar to that of the α-methyl group of 
flurbiprofen and makes hydrophobic contacts with Val-349 as well as Leu-359 (11). To 
further probe these interactions, we quantified the ability of naproxen to inhibit V349A, 
V349L, and V349I mutant enzymes. Naproxen inhibited V349A mCOX-2 with a similar 
potency and extent of inhibition as WT mCOX-2 (IC50 = 3.5 µM, 75% inhibition) but the 
V349I and V349L mutants were both more sensitive to inhibition (IC50 = 0.28 µM and 
0.35 µM, greater than 95% inhibition) (Figure 4). The increase in inhibition observed 
when naproxen was tested against V349I or V349L could arise from increased 
hydrophobic interactions between the α-methyl group and residue 349. This is consistent 
with the finding that 2-des-methylnaproxen is significantly less potent than naproxen 
against WT mCOX-2 (described in Chapter II).  
 The naproxen-COX-2 crystal structure shows that the p-methoxy group interacts 
with Trp-387 by van der Waals contacts to two carbon atoms of the sidechain, Cζ2 (3.4 
Å) and Cη2 (3.6 Å), the latter being the position of the sidechain unique spatially to 
tryptophans. Trp-387 is located at the top of the COX active site near the catalytic 
residue, Tyr-385, and has been shown to be a critical residue for the proper positioning of  
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Figure 4. Inhibition of Val-349 mCOX-2 mutants by naproxen. Naproxen (0.25 – 25 
µM)  was preincubated with WT mCOX-2 (), V349L (), and V349I () for 20 min 
prior to the addition of substrate (50 µM). Each reaction was terminated and analyzed as 
described under “Experimental Procedures.” IC50 values are reported under “Results”. 
Each data point is the average of at least two independent determinations. 
 
 
AA within the active site to yield the cyclooxygenase product, PGG2. The W387F 
mCOX-2 mutant enzyme forms relatively low amounts of PGG2 but increased amounts 
of the uncyclized product, 11-hydroxy-eicosatetraenoic acid (18). We tested the W387F 
mutant for sensitivity to naproxen inhibition. A higher protein concentration was used 
because of the mutant’s reduced catalytic activity. Naproxen had a minimal inhibitory 
effect on W387F exhibiting only 25% inhibition at 25 µM (Figure 2B). The W387F 
mutation has not been studied with other inhibitors, so we tested it against several other 
carboxylate-containing NSAIDs. Surprisingly, the IC50 values for diclofenac, 
flurbiprofen, and indomethacin against the W387F mutant enzyme were similar to 
previously reported values against WT enzyme (~87 nM, ~120 nM, and ~250 nM, 
respectively) (Figure 2B). Diclofenac and indomethacin, only form a single contact point 
to the tryptophan sidechain, at the Cζ2 position, which is closely mimicked by 
phenylalanine (7,11). While flurbiprofen forms interactions with both carbon atoms of 
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the Trp residue, they originate from a phenyl ring of the inhibitor that is already 
buttressed by other interactions, making the one with the Trp perhaps less important for 
binding.  In the case of naproxen, the oxygen of the p-methoxy group lies within van der 
Waals contact range only of the Trp sidechain. Therefore, the interaction between Trp-
387 and naproxen appears to be unique among carboxylate-containing NSAIDs.  
 
Figure 5. Inhibition of WT and W387F mCOX-2 by naproxen and naproxen 
analogs. Following a 20 minute preincubation of naproxen (A), p-ethyl naproxen (B), or a 
p-methylthio naproxen (C) with mCOX-2 () or W387F mCOX-2 (), [1-14C]-AA (50 
µM) was added and allowed to react for 30 seconds prior to termination with organic 
solvent. Concentrations of inhibitors ranged from 0.25 – 25 µM. Product formation was 
measured by TLC as described. Each data point is the mean of at least two independent 
experiments. 
 
As described in Chapter II, we synthesized a p-ethyl and p-methylthio naproxen 
analog and tested their ability to inhibit the COX enzymes. Both analogs were potent 
inhibitors of mCOX-2 but displayed a loss of potency against COX-1 as compared to 
naproxen. More remarkable however, both analogs inhibited W387F as well as they 
inhibited wild-type enzyme (Figure 5). The difference in sensitivity of W387F mCOX-2 
to naproxen and the p-ethyl and p-methylthio analogs prompted us to crystallize the 
complex of mCOX-2 with the p-methylthio naproxen derivative. A structure of this 
complex was refined at 2.3 Å resolution (Figure 6). Like naproxen, the inhibitor is bound 
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Figure 6. Crystal structure of p-methylthio naproxen bound to mCOX-2. A. 
Stereoview of the (FO-FC) difference electron density map contoured at 3.0σ prior to the 
addition of the inhibitor to the model.  B. Stereoview of the p-methylthio naproxen analog 
bound within the mCOX-2 active site. The carboxylate participates in hydrogen-bonding 
interactions with Arg-120 and Tyr-355 at the base of the active site; this interaction is 
represented by the dashed, yellow lines. 
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entirely within the main channel of the COX active site.  The closest equivalent atoms 
(distance = 0.2 Å) between the two compounds are the sulfur and oxygen atoms of the p-
methylthio and p-methoxy groups, respectively. The carboxylate tails of the compounds 
differ greatest in position, with the p-methylthio-substituted compound extending 
approximately 0.5 Å less deeply into the binding site. The p-methylthio naproxen analog 
adopts a binding conformation similar to that of naproxen, maintaining many of the same 
interactions with surrounding residues. For example, the carboxylate makes hydrogen-
bonding interactions with Arg-120 (2.9 and 3.0 Å) and Tyr-355 (2.5 Å) and the (S)- α-
methyl group makes hydrophobic contacts with Val-349 and Leu-359.  The naphthyl 
backbone participates in van der Waals interactions with Ala-527 and Gly-526 while the 
methylthio substitutent at the 6-position contacts Tyr-385 and Trp-387.  In contrast to 
naproxen, the p-methylthio naproxen analog is not within van der Waals distances of 
Leu-352. This difference arises from the fact that the Leu sidechain exhibits different 
conformations in the two structures, with that observed in the methylthio analog being 
consistent with that seen in the previously published NSAID:mCOX-2 co-crystal 
structures (3 of 4 monomers). No explanation for the rotation of the residue in the 
naproxen structure, or its failure to rotate in the methylthio derivative structure, is readily 
apparent. Comparison of the two crystal structures also indicates that Val-523 makes 
hydrophobic contacts with the naphthyl backbone of the p-methylthio naproxen analog 
but does not contact naproxen. This observation results from the relative shift of the 
compounds within the active site. 
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Discussion 
The pharmacological effects of NSAIDs, including naproxen, arise from the suppression 
of prostaglandin biosynthesis by inhibiting the cyclooxygenase enzymes, COX-1 and 
COX-2. Despite long-term use in the clinic, the molecular basis for COX inhibition by 
naproxen is not well-defined. We utilized an extensive mutagenesis study and X-ray 
crystallography, in combination with the previously described exploration of structure-
activity relationships, to identify the molecular determinants of COX inhibition by 
naproxen. By using a combined approach to probe the importance of naproxen-COX-2 
interactions, we were able to elucidate key interactions that would not have been 
identified by one technique alone.  We found critical interactions between the inhibitor 
and constriction site residues as well as a novel interaction with Trp-387 (Figure 2). 
Substitution of an ethyl or methylthio group for the p-methoxy substituent generated 
COX-2-preferring naproxen analogs that were unaffected by mutation of Trp-387 to Phe 
(Figure 5). We determined the X-ray crystal structures of both naproxen and the p-
methylthio analog bound to mCOX-2. The combination of mutagenesis, chemical 
elaboration of naproxen analogs, and structural studies, clearly defined the contribution 
of protein and inhibitor atoms to affinity (Figures 3 and 6).  
Naproxen appears to bind in the canonical conformation, with the carboxylic acid 
oriented towards the mouth of the mCOX-2 active site. Mutagenesis data suggests that 
one possibility regarding the nature of the interaction between the carboxylate moiety of 
naproxen and mCOX-2 is that the carboxylate interacts with Arg-120 via hydrogen 
bonding rather than ion-pairing interactions (Figure 3A). In contrast, the crystal structure 
of flurbiprofen in complex with mCOX-2 indicates that the carboxylate forms a salt 
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bridge with the guanidinium group of Arg-120 (11) Furthermore, previous studies have 
shown a 1000-fold increase in the IC50 value for flurbiprofen against R120Q oCOX-1 
compared to wild-type enzyme, suggesting that ion-pairing interactions are more 
important for inhibition by flurbiprofen than naproxen (19). 
Our data indicate that the α-methyl group inserts into a small hydrophobic cleft 
below Val-349, which may serve to anchor naproxen within the mCOX-2 active site and 
thereby reinforce the canonical binding orientation. The X-ray crystal structures of other 
2-arylpropionic acids and the diaryl heterocyclic compound, SC-558 bound to the COX 
enzymes indicate that the α-methyl group (or 4-trifluoromethyl, in the case of SC-558) is 
bound in a similar fashion to the naproxen structure (11,20). Carboxylate-containing 
COX inhibitors without a methyl group in the α-position utilize alternate interactions to 
reinforce binding within the COX active site. For example, the indolyl-2′-methyl group of 
indomethacin inserts into a hydrophobic pocket above Val-349 lined by Ala-527, Ser-
530, and Leu-531 to form a tightly bound complex (8,11). Similarly, while diclofenac 
binds in an inverted orientation with the carboxylate coordinated to Ser-530 and Tyr-385, 
a chlorine atom on the lower aniline ring also inserts into the hydrophobic pocket above 
Val-349 (7). 
A key interaction between naproxen and Trp-387 was uncovered during our 
mutagenesis screen by the finding that the W387F mutant was largely insensitive to 
naproxen inhibition. This interaction appears to be unique to naproxen as the same 
mutation had no appreciable effect on inhibition of mCOX-2 by diclofenac, flurbiprofen, 
or indomethacin (Figure 3B). The interaction with Trp-387 may result from a 
combination of hydrophobic packing of the methyl group and electrostatic interactions 
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with the polarized methoxy group. Unlike naproxen, the p-ethyl and p-methylthio analogs 
are effective inhibitors of W387F mCOX-2. This suggests that either the interaction with 
Trp-387 is not required for inhibition by the naproxen analogs or that they are able to 
interact more effectively with W387F COX-2 than is naproxen. Crystal structures of 
naproxen and the p-methylthio naproxen analog show the substituents at the 6-position 
oriented in a very similar fashion at the top of the COX active site providing no definitive 
basis for differential inhibition of W387F mCOX-2. Moreover, with the exception of 
Leu-352, there are no dramatically different interactions throughout the rest of the active 
site. The substitution of Phe for Trp at position 387 creates a larger active site for the 
mutant enzyme compared to WT mCOX-2. The ability of the p-ethyl and p-methylthio 
naproxen analogs to inhibit W387F mCOX-2 as well as WT suggests that the analogs 
may be able to adopt an alternate conformation in the larger active site of W387F 
mCOX-2 compensating for the loss of the interaction with Trp-387 in the wild-type 
enzyme.  
Crystallographic studies may provide some insight into the nature of the COX-2 
selectivity of the p-ethyl and p-methylthio analogs compared to naproxen. The crystal 
structure of the p-methylthio naproxen analog bound to mCOX-2 is suggestive of 
hydrophobic interactions between Val-523 and the proximal ring of the napthyl 
backbone. Thus, steric interactions at the top of the channel may put additional pressure 
on Val-523 near the base of the active site so that inhibition of COX-1, where a bulkier 
isoleucine is located at residue 523, is significantly more difficult. Mutation of Val-523 to 
Ile in COX-2 greatly reduces the selectivity of potent COX-2-selective inhibitors like 
celecoxib and rofecoxib. Consistent with this hypothesis, the naproxen analogs were 
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unable to significantly inhibit V523I mCOX-2. However, interpretation of these results is 
difficult, as it has previously been reported that a V523I mutation in the hCOX-2 
background completely abrogates inhibition of hCOX-2 by naproxen as measured by a 
PGE2 ELISA assay (21). Consistent with these results, naproxen was not an effective 
inhibitor of V523I mCOX-2 in our standard IC50 assay; the maximal extent of inhibition 
was approximately 20% (data not shown). This appears to be the first case of a non-
COX-2-selective inhibitor making a key interaction with this area of the active site. 
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CHAPTER IV 
 
DIFFERENTIAL SENSITIVITY AND MECHANISM OF INHIBITION OF 
CYCLOOXYGENASE-2 OXYGENATION OF ARACHIDONIC ACID AND 2-
ARACHIDONOYLGLYCEROL BY RAPIDLY REVERSIBLE NON-STEROIDAL 
ANTI-INFLAMMATORY DRUGS 
 
 
 
Introduction 
Cyclooxygenase-2 (COX-2) oxygenates a range of fatty acyl substrates including 
fatty acids, esters, and amides. Arachidonic acid (AA) and the endocannabinoid 2-
arachidonoylglycerol (2-AG) are the best acid and ester hCOX-2 substrates, respectively, 
and display comparable kcat/Km ratios for oxygenation (1). Despite this similarity, this 
laboratory recently reported that COX-2 oxygenation of 2-AG is dramatically more 
sensitive to inhibition by ibuprofen and mefenamic acid than is oxygenation of AA (2). In 
fact, these compounds, which have been considered relatively weak COX inhibitors, 
inhibit 2-AG oxygenation at concentrations that are orders of magnitude lower than the 
concentrations required for inhibition of AA oxygenation. Further, ibuprofen and 
mefenamic acid appear to be competitive inhibitors of AA oxygenation, but non-
competitive inhibitors of 2-AG oxygenation by COX-2 (Figure 1).  
These data suggest that ibuprofen and mefenamic acid inhibit COX-2 oxygenation 
of AA and 2-AG by different mechanisms and with different potencies. An interpretation 
of the experimental findings that is consistent with recent results establishes that the two 
subunits of the homodimeric COX-2 protein are not identical once substrate or inhibitor 
is bound (3). In the case of 2-AG oxygenation, binding of a single molecule of ibuprofen 
or mefenamate at one subunit prevents productive binding of 2-AG at the other subunit  
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Figure 1. Inhibition of mCOX-2 oxygenation of AA and 2-AG by ibuprofen. 
Ibuprofen and substrate were mixed in an oxygraph cell, and the reaction was initiated by 
addition of COX-2. The initial velocity of O2 uptake was determined from a tangent to 
the most rapidly descending portion of the curve. Data were fit using the Michaelis-
Menten model. (A) Ibuprofen at 0 µM (), 50 µM (○), 200 µM (▲), and 300 µM (●). (B) 
Instantaneous COX-2 inhibition of 2-AG oxidation by ibuprofen at 0 µM (), 0.5 µM 
(), 1.25 µM (), and 2.5 µM (●). Reproduced from (2). 	  	  	  
	  
Figure 2. Model for differential inhibition 2-AG and AA oxygenation by COX-2. The 
uninhibited mCOX-2 homodimer (blue) is able to effectively metabolize both AA and 2-
AG to form PGG2 and PGG2-G. Binding of an inhibitor (yellow) to a single monomer 
(green) precludes the productive binding of 2-AG in the partner monomer (red) but still 
allows for AA oxygenation. Metabolism of AA is inhibited only when an inhibitor 
occupies both active sites of the COX dimer as shown on the far right. 	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(Figure 2). This hypothesis is consistent with the apparent non-competitive inhibition of 
2-AG oxygenation by ibuprofen and mefenamic acid. In contrast to the observations with 
2-AG, inhibition of COX-2 oxygenation of AA by ibuprofen or mefenamate requires 
much higher concentrations of inhibitor and displays kinetic behavior typical of 
competitive inhibition. The most straightforward interpretation of these results is that 
inhibition of AA oxygenation requires inhibitor molecules to bind in both active sites. 
Binding in the first active site is necessary but not sufficient to inhibit AA oxygenation; 
inhibition is only observed when the second molecule of inhibitor competes with AA for 
binding at the remaining active site (Figure 2).   
To explore the generality of this phenomenon, we surveyed the inhibition of 
COX-2-dependent 2-AG and AA oxygenation by different classes of NSAIDs. The 
results of these studies indicate that compounds classified as weak, reversible inhibitors 
of AA oxygenation are potent inhibitors of 2-AG oxygenation by COX-2 while 
compounds classified as slow, tight-binding inhibitors exhibit potent inhibition of both 2-
AG and AA oxidation with comparable IC50 values for both substrates.  	  	  
Experimental Procedures 
 
Materials. mCOX-2 was expressed and purified as described (4). AA was purchased 
from Nu-Check Prep, Inc.  (Elysian, MN) and prepared as a stock solution in DMSO. 2-
AG and prostaglandin E2-d4 (PGE2-d4) was purchased from Cayman Chemical Company 
(Ann Arbor, MI). The internal standard prostaglandin E2-glycerol-d5 (PGE2-G-d5) was 
synthesized by transesterification from PGE2 and	   glycerol-d5 purchased from Sigma 
	   111	  
(Milwaukee, WI). Naproxen, diclofenac, flurbiprofen, indomethacin and celecoxib were 
also purchased from Sigma-Aldrich (Milwaukee, WI).  Lumiracoxib, 2′-des-
methylindomethacin (DM-INDO), and rofecoxib were synthesized according to 
published methods (5-7). Reagents used in the crystallization of mCOX-2 were purchased 
from Hampton Research (Aliso Viejo, CA).	  	  
Inhibition of AA and 2-AG oxygenation as measured by oxygen uptake.  For AA 
experiments, 440 nM mCOX-2 was preincubated with inhibitor for 2 min at 37 °C prior 
to the addition of 50 µM AA. For experiments in which 2-AG was used as the substrate, 
the concentration of mCOX-2 was increased to 890 nM to allow for a similar extent of 
oxygenation of 2-AG compared to AA. Because of the relatively low sensitivity of the 
oxygen monitor, high protein concentrations were required to obtain measurable 
oxygenation.  Initial reaction velocity was determined from the linear portion of oxygen 
uptake curves as measured by an Instech 210 Fiber Optic oxygen monitor  (Plymouth 
Meeting, PA) and normalized to a DMSO control.  	  	  
Analysis of NSAID inhibition of AA and 2-AG oxygenation by mCOX-2 by mass 
spectrometry - A fixed concentration of mCOX-2 (approximately 50 nM for 5 µM 
substrate or 200 nM for 50 µM substrate) was incubated with inhibitor (or DMSO 
control) for five or twenty minutes at 37 °C before the addition of substrate; pre-
incubation time was determined based on previous reports of the time necessary to 
achieve maximal inhibition. The concentration of inhibitor ranged from 16 nM – 25 µM.   
The enzyme-inhibitor complex was allowed to react with 5 or 50 µM AA or 2-AG	  for 30 
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seconds before quenching with an extraction solution of ethyl acetate with 0.5% acetic 
acid and deuterated internal standards. The organic layer was separated and evaporated to 
near-dryness under nitrogen and stored at -20 °C until analysis. Samples were 
reconstituted with 1:1 MeOH:water (v/v) and analyzed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis. The solvent system consisted of 5 mM 
ammonium acetate, pH 3.5 (Buffer A) and acetonitrile with 6% Buffer A (v/v) (Buffer 
B). Samples were chromatographed using a 50 Å C18 Luna column (5 x 0.2 cm, 3 μm) 
using an isocratic method at 34% B with a flow rate of 375 mL/min. Prostaglandin (PG) 
and glycerol prostaglandin (PG-G) products were measured by SRM using the following 
transitions: for PGE2/D2  m/z 370  317, for PGE2/D2-d4  m/z 374  321, for PGE2/D2 - 
G m/z 444  391 and for PGE2/D2 - G-d5 m/z 449 396. In order to quantitate PG and 
PG-G production, the ratio of the area of the peak to its corresponding internal standard 
was determined and normalized to a DMSO control.	  	  
	  
Co-crystallization of mCOX-2 and DM-INDO. Purification and crystallization were 
performed according to the methodology described for the co-crystallization of naproxen 
and mCOX-2 (8). Data collection and refinement statistics are shown in Table 1.  	  
Results 
Indomethacin and DM-INDO. Several arylcarboxylic acids or diarylheterocycles are 
slow, tight-binding inhibitors of COX-2 (9). These compounds exhibit low Kd values for 
binding and potent inhibition but only after a lengthy preincubation period. The 
indoleacetic acid derivative indomethacin is a classic slow, tight-binding inhibitor of both 
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COX-2 and COX-1 (10). Inhibition of AA oxygenation by COX-2 requires a	  
preincubation period of up to 15 min, and its inhibition potency increases dramatically 
during this time. Following preincubation of enzyme and inhibitor, indomethacin 
displayed an IC50 of 2 µM for inhibition of AA oxygenation and 5.5 µM for inhibition of 
2-AG oxygenation as measured by an oxygen uptake assay (Figure 3). It has been 
reported previously that binding of a single molecule of indomethacin to a COX 
homodimer is sufficient to maximally inhibit AA oxygenation (11). The similar IC50 
values for inhibition of AA and 2-AG suggests that a single indomethacin molecule 
bound in one subunit is sufficient to inhibit the oxygenation of either a fatty acid or fatty 
acid ester substrate in the other subunit.	  
	  
Figure 3. Determination of IC50 values for the inhibition of mCOX-2 oxygenation of 
AA and 2-AG by indomethacin and DM-INDO. mCOX-2 was preincubated with 
indomethacin (●) or DM-INDO() for 2 min before the addition of 2-AG. For AA, 
maximal inhibition was achieved following a 15 min preincubation with indomethacin 
(○) and a 2 min preincubation with DM-INDO(). Inhibitor concentrations ranged from 
250 nM to 500 µM. Following the addition of 50 µM substrate, initial rates of oxygen 
uptake were determined and normalized to a DMSO control. 	  	  
The steep dose-response curve observed for the inhibition of 2-AG oxygenation 
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by indomethacin may indicate that the Kd’s of these inhibitors are	   lower than the	  
concentration of enzyme used in the oxygen uptake assay (12).  In this case, the measured 
IC50 values are a reflection of the enzyme concentration and not the true Kd. Therefore, an 
alternative assay was employed that measured PGD2/E2-G or PGD2/E2 formation by LC-
MS/MS following a 15 min preincubation of inhibitor with enzyme to assure maximal 
inhibition of the oxygenation of both substrates.  Saturating concentrations of both 2-AG 
and AA (50 µM for both) were used as in the oxygen uptake assay. The increased 
sensitivity of the mass-spectrometry assay allowed the use of enzyme concentrations 
significantly lower than the concentration required for the oxygen uptake assay (200 nM 
versus approximately 900 nM for 2-AG). The IC50 values for inhibition of AA and 2-AG 
by indomethacin were 180 nM and 10 nM,	   respectively; complete inhibition was 
observed for both substrates. These findings are in agreement with the trends observed in 
the oxygen uptake experiments in that indomethacin potently inhibits the oxygenation of 
both AA and 2-AG with similar IC50 values.	  	  
A major determinant of the slow, tight binding of indomethacin to COX-2 is 
insertion of the 2′-methyl group on the indole ring into a hydrophobic depression in the 
side of the COX-2 active site (6). Removal of the 2′-methyl group generates a molecule, 
DM-INDO, which exhibits rapid reversible inhibition of AA oxygenation with a much 
higher IC50. Figure 3 demonstrates that removal of the 2′-methyl group from 
indomethacin increases the IC50 for inhibition of AA oxygenation from 2 µM for 
indomethacin to ~500 µM for DM-INDO. In contrast to the results with AA, removal of 
the 2′-methyl group from indomethacin has no effect on the inhibition of 2-AG 
oxygenation; the IC50 for inhibition of 2-AG oxygenation by DM-INDO is 6.8 µM, 
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essentially the same as the IC50 of indomethacin (Figure 3). Like indomethacin,	  DM-
INDO has a steep dose-response curve for the inhibition of 2-AG. Therefore, we 
evaluated the inhibition of both AA and 2-AG oxygenation by DM-INDO in the LC-
MS/MS assay. The IC50 value for 2-AG was 110 nM (100% inhibition), while no value 
could be determined for inhibition of AA oxygenation at concentrations of DM-INDO up 
to 25 µM (30% inhibition)(Table II). Therefore, like the reversible inhibitors ibuprofen 
and mefenamic acid, DM-INDO appears to be a weak inhibitor of COX-2 mediated 
oxygenation of AA, but a potent inhibitor of 2-AG oxygenation.	  	   A conformational change at the dimer interface upon inhibitor binding is thought 
to be associated with the negative cooperativity between COX monomers. The results 
above suggest that indomethacin and DM-INDO utilize different mechanism of inhibition 
to prevent 2-AG oxygenation. To examine potential differences at the dimer interface 
following the binding of indomethacin compared to DM-INDO, and to verify that 
indomethacin and DM-INDO occupy similar conformations within the mCOX-2 active 
site, we determined the 2.4 Å crystal structure of DM-INDO bound within the COX-2 
active site; the 2.9 Å crystal structure of indomethacin bound to COX-2 was reported by 
Kurumbail et al. in 1996 (13). As shown in Figure 4, clear electron density for DM-
INDO was observed in both monomers of the COX-2 homodimer. Like indomethacin, 
DM-INDO appears to bind completely within the COX active site, with the carboxylic 
acid coordinated to active site residues Try-355 and Arg-120. The p-chlorobenzoyl 
moiety of DM-INDO also occupies a similar conformation to that of indomethacin at the 
apex of the COX active site channel. While it is difficult to make definitive conclusions 
regarding differences in the binding mode of indomethacin and DM-INDO due to the low 
	   116	  
to moderate resolution of the structures, it appears that the indole ring and benzoyl	  
oxygen of DM-INDO occupy slightly altered conformations compared to indomethacin 
(Figure 4). This can likely be attributed to the absence of the 2′-methyl group, which 
anchors indomethacin in a small hydrophobic pocket comprised of Val-349, Leu-531, 
Ser-530 and Ala-527. Insertion of the 2′-methyl group of indomethacin into this pocket is 
the major determinant of time-dependent inhibition of COX, and is thought to result in a 
conformational change of the enzyme-inhibitor complex leading to functionally 
irreversible inhibition.  
We hypothesize that binding of a single molecule of inhibitor in one active site is 
sufficient to prevent the productive binding of 2-AG in the active site of the partner 
monomer. This hypothesis is based on recent work that indicates that the two monomers 
of each COX enzyme are functionally interdependent and that binding of a substrate or 
inhibitor at one active site alters the properties of the other active site (3). The 
communication between subunits occurs through the dimer interface (14). Further, it has 
recently been reported that a shift in the position of the loop containing residues 121-127 
at the dimer interface is observed when celecoxib is bound in one monomer of the 
oCOX-1 homodimer, while the active site of the partner monomer remains empty (15).  
However, the concentration of inhibitor was seven times that of the enzyme in the 
crystallization conditions used to determine the mCOX-2:DM-INDO structure so that 
both monomers appeared to be fully occupied with DM-INDO, and no changes were 
observed along the dimer interface.  
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Table 1. Crystallographic data collection and refinement statistics. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
a Values in parentheses correspond to the highest resolution shells. 
b Rmerge = Σhkl Σj =1,N ⏐〈Ihkl〉 - Ihklj⏐/ Σhkl Σj =1,N ⏐Ihklj⏐where the outer sum (hkl) is taken over 
the unique reflections. 
c Rf = Σhkl ||Fo,hkl - k|Fc,hkl||/Σhkl|Fo,hkl|, where |Fo,hkl| and |Fc,hkl| are the observed and calculated 
structure factor amplitudes, respectively. 
d Rfree is same as for Rf for the set of reflections (5-10% of the total) omitted from the 
refinement process. 
APS, Advanced Photon Source; NE-CAT, North Eastern Collaborative Access Team; 
rms deviation, root mean square deviation. 
Beamline APS (NE-CAT) 
Wavelength (Å) 0.979 
Temperature (K) 100 
Space group I222 
Unit cell (a, b, c; Å)  123.23, 132.59, 180.29 
Resolution range (Å) 30-2.5 
Highest resolution shell 2.59-2.5 
No. of measurements 1280205 
No. of unique reflections 49403 (4936) 
Redundancy 3.7 (3.7) 
Completeness (%) 97.1 (98.6) 
Rmerge (%) 10.6 (47.2) 
Signal to noise (I/σI) 15.1 (2.5) 
Solvent content (%) 59.6 
Model composition (asymmetric unit)  
     No. amino acid residues 1102 
     No. water molecules 405 
Rf (%) 19.0 
Rfree (%) 25.6 
rms deviation  
     Bond lengths (Å) 0.009 
     Bond angles (°) 1.3 
B-factors  
     Protein 39.445 
     Ligand 35.052 
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  Monomer	  A	   	   	   	   	   	  	  	  Monomer	  B	  
	  	   	  
	  
Figure 4. Crystal structure of DM-INDO bound in the active site of COX-2. A. 2FO-
FC difference electron density map contoured at 1.0σ for DM-INDO in the active site of 
mCOX-2. B. Stereoview of an overlay of DM-INDO (green) and indomethacin (purple) 
in the mCOX-2 active site. PDB ID for indomethacin structure: 4COX. 
A 
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Naproxen. The non-selective NSAID naproxen displays a unique kinetic mechanism of 
COX inhibition. It is clear that naproxen does not associate with the COX enzymes by a 
single-step mechanism (like ibuprofen or mefenamic acid), as a short preincbuation time 
is required for maximal inhibition. However, in contrast to slow, tight-binding inhibitors 
like indomethacin, the enzyme-inhibitor complex remains readily reversible.  Previous 
studies describe this mode of inhibition as “mixed”, which was characterized by an initial 
time-dependent loss of enzyme activity followed by a non-zero plateau (16). As such, it 
was of interest to determine whether naproxen would be a more potent inhibitor of 2-AG 
compared to AA oxygenation similar to other rapidly reversible inhibitors, despite 
interacting with the enzyme in a time-dependent manner. Following a short 
preincubation, naproxen inhibited AA oxygenation by mCOX-2 with an IC50 value of 4.5 
µM while the IC50 value was 430 nM for 2-AG. These results indicate that naproxen is, in 
fact, a more potent inhibitor of 2-AG oxygenation compared to AA (Figure 5). In 
subsequent experiments, the substrate concentration was reduced from a saturating 
concentration of 50 µM to 5 µM, which is closer to the reported Km values for AA and 2-
AG. Under these conditions, the IC50 values decreased (AA: 340 nM, 2-AG: 30 nM) but 
the fold-change in potency for 2-AG versus AA was similar (Figure 5). The shift in IC50 
values may also be partially attributed to differing assay conditions as values for 50 µM 
substrate were determined by monitoring the change in the initial rate of oxygen uptake 
as measured by an oxygen electrode, while the IC50 values for reduced substrate 
concentrations were determined by monitoring decrease in product formation using mass 
spectrometry. 
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Figure 5. Substrate-selective inhibition of mCOX-2 by naproxen. A: Naproxen (15.6 – 
4000 nM) was preincubated with 45 nM mCOX-2 for 5 minutes before the addition of 5 
µM AA or 2-AG for 30 seconds. Product formation was analyzed using LC-MS/MS as 
described in Experimental Procedures. B:  Naproxen (20 nM - 100 µM) was preincubated 
with 200 nM mCOX-2 for 2 min prior to the addition of 50 µM substrate. Oxygen uptake 
was monitored for 30 sec to determine the initial rate of the reaction then normalized to 
DMSO control.  	  
Screening additional molecules. A series of compounds previously classified as rapid, 
reversible inhibitors or slow, tight binding inhibitors were compared for their ability to 
inhibit 2-AG or AA oxygenation by COX-2 using the LC-MS/MS assay described above. 
The results are summarized in Table 1 and are consistent with the initial findings for 
ibuprofen, mefenamic acid, and indomethacin.  Compounds classified as rapid, reversible 
inhibitors are potent inhibitors of 2-AG oxidation but weaker inhibitors of AA oxidation.  
In contrast, compounds that are classified as slow, tight-binding inhibitors exhibit potent 
inhibition of both 2-AG and AA oxidation by COX-2 with comparable IC50 values for 
both substrates.  Within inhibitor class, no differences in behavior are observed for 
compounds that are COX-2-selective inhibitors or non-selective inhibitors of both COX 
enzymes. 
A dramatic example of the differential inhibitory potency of a rapid, reversible 
inhibitor is provided by lumiracoxib.  Lumiracoxib is a COX-2-selective inhibitor of the 
B A 
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arylacetic acid class that exhibits the highest selectivity for COX-2 of	  all inhibitors in the 
ex vivo human whole blood assay.  Previous work from our laboratory established that 
lumiracoxib is a poor inhibitor of AA oxygenation at saturating concentrations of 
substrate.  This is confirmed in Figure 6 by the near complete absence of inhibition even 
at high inhibitor concentrations.  In contrast, lumiracoxib is an extremely potent inhibitor 
of 2-AG oxygenation with an IC50 of 40 nM.  In fact, lumiracoxib is one of the most 
potent inhibitors of COX-2 oxygenation of 2-AG we have evaluated despite the fact that 
it was assayed at a saturating concentration of 2-AG (50 µM).  The potent inhibitory 
activity of lumiracoxib against 2-AG oxygenation is especially interesting because the 
close structural analog, diclofenac, is a potent slow, tight-binding inhibitor of both 2-AG 
and AA oxygenation (Figure 6).  The poor inhibition of AA oxygenation by lumiracoxib 
is partly a reflection of the fact that it is a competitive inhibitor of AA oxidation, and the 
assays summarized in Figure 6 were performed at saturating substrate concentrations.  
When assays are performed at 5 µM, which is close to the Km value for both substrates, 
inhibition of AA oxygenation is detectable (IC50 = 140 nM).  However, even under these 
conditions, lumiracoxib exhibits considerable selectivity for inhibition of 2-AG 
oxygenation (IC50 = approximately 3 nM). 	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Table 2. IC50 values for the inhibition of COX-2 oxygenation of AA and 2-AG by 
various COX inhibitors.  	   Inhibitor	   50	  µM	  AA	   50	  µM	  2-­‐AG	  Ibuprofen*	   7	  µM	   20	  nM	  Mefenamic	  Acid*	   180	  µM	   210	  nM	  DM-­‐INDO	   >	  25	  µM	   110	  nM	  Lumiracoxib	   no	  inhib.	   40	  nM	  reversible	   SC-­‐58076	   >	  4	  µM	   40	  nM	  	   	   	   	  Diclofenac	   60	  nM	   50	  nM	  Flurbiprofen	   130	  nM	   30	  nM	  INDO	   180	  nM	   10	  nM	  Celecoxib	   80	  nM	   95	  nM	  slow,	  tight	  binders	   Rofecoxib	   520	  nM	   85	  nM	  
Enzyme and inhibitor were pre-incubated for 15 minutes prior to the addition of 50 uM 
substrate for 30 seconds. Reactions were quenched with organic solvent containing 
deuterated internal standards. Product formation was analyzed by LC-MS/MS using SRM 
and normalized to DMSO control. *AA oxygenation was measured using an oxygen 
electrode. Values for ibuprofen and mefenamic acid were taken from (2). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 6.  Inhibition of mCOX-2 oxygenation of AA and 2-AG by lumiracoxib and 
diclofenac. Panel A: mCOX-2 and lumiracoxib were pre-incubated for 5 minutes before 
the addition of 50 µM AA () or 2-AG () for 30 seconds. Panel B: Following a 15 
minute incubation of diclofenac and mCOX-2, 50 µM AA () or 2-AG () was added 
for 30 seconds. Reactions were quenched with ethyl acetate containing 0.5% acetic acid 
(v/v) and internal standards. PG or PG-G formation was measured using a selected 
reaction monitoring LC-MS/MS method.  
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Discussion 
Rome and Lands first demonstrated that some COX inhibitors display rapid, 
reversible inhibition, whereas others exhibit slow, tight-binding inhibition after the initial 
rapid, reversible interaction with the enzyme (10). The rapid, reversible inhibitors are 
often relatively weak inhibitors of AA oxygenation, whereas the slow, tight-binding 
inhibitors are more potent. The slow, tight-binders exhibit very low dissociation rates so 
they are poorly reversible even in the presence of saturating concentrations of AA. The 
validity of the two-step mechanism of inhibition has been demonstrated repeatedly and in 
some cases extended, as exemplified by certain diarylheterocycles, which demonstrate a 
second time-dependent step responsible for COX-2-selective inhibition (17-19). 
Subsequent work has revealed that for several slow, tight-binding inhibitors (e.g., 
indomethacin, flurbiprofen) association of only a single molecule of inhibitor is sufficient 
to inhibit the activity of both subunits, and this can be understood by the recent discovery 
that the two subunits communicate through the dimer interface (3). 
Our data suggest that binding of a single molecule of a rapidly reversible or slow, 
tight-binding inhibitor is sufficient to cause noncompetitive inhibition of 2-AG 
oxygenation but only slow, tight-binders inhibit AA oxygenation under these conditions. 
These observations indicate that although all of the inhibitors induce conformational 
changes in the second subunit following binding in the first subunit, there are differences 
in the nature of the conformational changes induced as judged by the differential effects 
on 2-AG and AA binding in the second subunit. In addition, this differential sensitivity to 
inhibition reveals differences in the binding of 2-AG and AA that are not anticipated by 
the similarities in the kcat/Km value for oxygenation of the two substrates (1). 
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It is intriguing to consider the possibility that the greater potency for inhibition of 
2-AG oxygenation exhibited by certain NSAIDs against purified protein has implications 
for understanding the pharmacological properties of these compounds in vivo. The 
endocannabinoids 2-AG and anandamide are selectively oxygenated by COX-2 to form 
PG-Gs and prostaglandin-ethanolamides (PG-EAs), respectively (20). Evolving data 
indicate that these neutral PG derivatives exhibit biological functions distinct from those 
of AA-derived PGs (21). Endocannabinoids bind and activate the cannabinoid receptors 
CB1 and CB2 leading to the regulation of a wide range of physiological and behavioral 
functions including analgesia and anti-inflammatory effects. PG-G and PG-EA formation 
may be viewed as an inactivation pathway for endocannabinoids and therefore, inhibition 
of endocannabinoid metabolism by COX-2 inhibitors may be related to the anti-
inflammatory and analgesic properties of these drugs. 
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CHAPTER V 
 
SUBSTRATE-SELECTIVE INHIBITION OF CYCLOOXYGENASE-2 CATALYZED 
ENDOCANNABINOID OXYGENATION BY (R)-PROFENS 
 
 
 
Introduction 
 
The endocannabinoids 2-arachidonoylglycerol (2-AG) and 
arachidonoylethanolamide (AEA), exert analgesic and anti-inflammatory effects through 
their actions at the cannabinoid receptors CB1 and CB2. As discussed in Chapter I, they 
are also substrates for fatty acid oxygenases such as lipoxygenases and cyclooxygenases 
(COXs), which convert them to bioactive oxygenated metabolites.  2-AG and AEA are 
oxygenated efficiently by COX-2 but not COX-1 to prostaglandin glycerol esters (PG-
Gs) and prostaglandin ethanolamides (PG-EAs), respectively, which are potent activators 
of calcium mobilization in macrophages, trigger miniature inhibitory postsynaptic 
currents in neurons, induce mechanical allodynia, and stimulate thermal hyperalgesia (1-
6). 2-AG and AEA are rapidly hydrolyzed by monoacylglycerol lipase or fatty acid amide 
hydrolase, respectively, to AA, which terminates endocannabinoid signaling but produces 
a fatty acid that is converted to leukotrienes and prostaglandins inter alia. Thus, 2-AG 
and AEA are at the nexus of a complex cascade of bioactive lipid production, 
inactivation, and signaling. 
The importance of endocannabinoids as naturally occurring analgesic agents 
provides a potential mechanism for inhibition of neuropathic pain through the 
development of agents that prevent endocannabinoid metabolism at sites of 
neuroinflammation. Since COX-2 is induced at sites of neuroinflammation, non-steroidal 
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anti-inflammatory drugs (NSAIDs), whether non-selective or selective for COX-2, may 
contribute to endocannabinoid-sparing by preventing COX-2-mediated oxygenation of 2-
AG and AEA. The ability to focus selectively on endocannabinoid-sparing by NSAIDs 
would appear to be limited by their concomitant inhibition of AA oxygenation, which 
confers a risk of gastrointestinal and cardiovascular toxicity. However, our laboratory 
recently reported that NSAIDs that interact with COX-2 in a reversible manner are 
significantly more potent inhibitors of 2-AG oxygenation than AA oxygenation by 
purified COX-2 – a phenomenon we dubbed “substrate-selective inhibition” (7). The 
explanation for this dramatic substrate-selective inhibition is based on the recent 
discovery that binding of substrate or inhibitor to the first monomer of the COX 
homodimer is communicated to the second monomer through the extensive dimer 
interface, effectively transforming the protein into a conformational heterodimer (8,9). 
We hypothesize that binding of a rapidly reversible inhibitor in a single monomer of the 
COX homodimer is sufficient to block the productive binding of 2-AG, but not AA, in 
the partner monomer. To inhibit AA oxygenation, a molecule of inhibitor must be present 
in both active sites. For slow, tight-binding inhibitors (e.g. flurbiprofen and 
indomethacin), previous work has shown that a single molecule of inhibitor effectively 
inhibits AA oxygenation in both subunits of the COX homodimer (8,10). In accordance 
with these studies, we found that slow, tight-binding inhibitors prevent AA and 2-AG 
oxygenation with similar IC50 values. 
These and related findings shed important new insights into the mechanisms of 
inhibition of COX proteins by NSAIDs and may serve as a model for ligand-binding by 
other multimeric proteins. Further, development of a truly “substrate-selective” inhibitor 
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provides a potential mechanism to prevent endocannabinoid oxygenation at the sites of 
neuroinflammation without affecting AA oxygenation. We report here that (R)-
enantiomers of 2-arylpropionic acid NSAIDs, which do not effectively inhibit AA 
oxygenation, are, in fact, able to bind in the COX active site to block COX-2-mediated 
oxygenation of 2-AG.  	  
Experimental Procedures 
 
Materials. mCOX-2 was expressed and purified as previously described (11). (R)-
flurbiprofen, 2-AG, PGE2-d4, and 5-phenyl-4-pentenyl hydroperoxide (PPHP) were 
obtained from Cayman Chemical Company (Ann Arbor, MI). (R)-naproxen as well as 
reagents for the synthesis of PGE2-G-d5, PGE2 and glycerol-d5, were purchased from 
Sigma-Aldrich (Milwaukee, WI). (R)-ibuprofen was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). AA was obtained from Nu-Check Prep, Inc.  (Elysian, 
MN).  Crystallization reagents were purchased from Hampton Research (Aliso Viejo, 
CA). 	  
COX inhibition assay. Hematin-reconstituted mCOX-2 (200 nM) was preincubated with 
varying concentrations of inhibitor (63 nM to 25  µM) for 15 minutes prior to the 
addition of 50 µM AA or 2-AG at 37 °C. For 5 µM substrate, the concentration of COX-
2 was reduced to 45 nM. Reactions were carried out in 100 mM Tris buffer containing 
500 µM phenol, pH 8.0. The reaction was quenched after 30 seconds by the addition of 
ice-cold quench solution followed by vigorous mixing. The quench solution consisted of 
ethyl acetate with 0.5% acetic acid (v/v) and deuterated internal standards, PGE2-d4, and 
PGE2-G-d5. The organic layer was removed and evaporated to near-dryness under 
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nitrogen. The residue was reconstituted with 1:1 MeOH:H20 (v:v), and PGD2/E2 and 
PGD2/E2-G production was monitored by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS).  Samples were chromatographed using an isocratic method 
of 66% 5 mM ammonium acetate, pH 3.5 and 34% acetonitrile (v/v) at a flow rate of 375 
mL/min on a 50 Å C18 Luna column (5 x 0.2 cm, 3 micron). To quantitate product 
formation, a selected reaction monitoring method was utilized to measure the following 
transitions: PGE2/D2 m/z 370  317, PGE2/D2-d4  m/z 374  321, PGE2/D2 - G m/z 444 
 391 and PGE2/D2 - G-d5 m/z 449 396. The amount of PG products was determined 
by normalization of the peak area of the analyte to the peak area of internal standard. The 
percent of COX activity remaining in the presence of inhibitor was determined by 
normalization to a DMSO control. 	  
 
Peroxidase activity assay – Assays were performed as described by Markey et al. with 
the following modifications (12). Hematin-reconstitued mCOX-2 (100 nM) in 100 mM 
Tris-HCl buffer, pH 8, was incubated with inhibitor (100 µM – 5 mM) in the presence of 
200 µM phenol at 37 °C for 5 min. The reaction was initiated by the addition of PPHP 
(100 µM) and terminated after 5 min by the addition of ice cold quench solution (ethyl 
acetate + 0.5% acetic acid (v/v)) followed by vigorous mixing and centrifugation at 4 °C. 
The organic layer was removed, evaporated to dryness under nitrogen, and reconstituted 
in 300 mL of a 1:1 solution of methanol and water. Samples were separated by reverse 
phase HPLC with UV detection at 254 nM. Samples are chromatographed utilizing a C8 
reverse-phase column (Luna C8 3 µm HPLC column (150 x 2.00 mm)) with a gradient 
elution beginning at 50% (v/v) methanol/water increasing to 90% methanol (v/v) over 9 
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minutes and held at 90% methanol (v/v) for 10 additional minutes at a flow rate of 0.20 
mL/min. The concentrations of the analytes were estimated from the area of the 
representative peak. Peroxidase activity was measured by the percent conversion of 
PPHP to 5-phenyl-4-pentenyl alcohol, PPA, using the equation: [PPA]/([PPA]+[PPHP]).  
 
Crystallography. COX-2 was expressed and purified as previously described. Purified 
protein was prepared for crystallization, and hanging-drop crystallization experiments 
were set up according to published methods (13). All diffraction data were collected at 
100 K at the beamline 24ID-E located at the Advanced Photon Source, using an ADSC 
Quantum 315 charge-coupled-device-based detector. Diffraction data were processed 
with HKL2000 (14).  Initial phases were determined by molecular replacement using a 
search model (PDB 3NT1) with MOLREP (15). A solution having two molecules in the 
asymmetric unit was obtained. The model was improved with iterative rounds of model 
building in Coot and refinement in PHENIX (16,17). Data collection and refinement 
statistics are shown in Table I.  Molecular graphics were generated using PyMOL (18). 	  
Inhibition of COX in dorsal root ganglion cells (DRGs). Dorsal root ganglion neurons 
and glia were harvested from E14 mouse embryos and plated onto collagen coated dishes 
at 100,000 cells per dish. The cells were cultured in 3 mL of medium consisting of 1.5 
mL Lonza’s ultraculture and 1.5 mL L-glutamine with Neurobasal, N2, and B27 
supplements, with 3% Hyclone fetal bovine serum, 1% penicillin or streptomycin, and 50 
ng/ml mouse nerve growth factor), and the medium was replaced every 3-4 days. For the 
inhibition assay, cells were stimulated overnight with 20 ng/mL of granule macrophage 
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colony stimulating factor. The following morning, the medium was replaced, and the 
cells were treated with 100 ng/mL lipopolysaccharide, 20 units/ml mouse interferon γ, 
and 10 µM 15(S)-HETE. The cells were treated with varying concentrations of inhibitor 
(or DMSO control) 2 hours after medium replacement, and 2 µM ionomycin 3 hours after 
medium replacement. The cell medium was collected 3 hours after ionomycin treatment 
and extracted with two equivalents of ethyl acetate with 1% glacial acetic acid (v/v) 
spiked with deuterated standards of PGs. The extracts were evaporated under nitrogen 
and reconstituted in 1:1 methanol and water (v/v). Samples were analyzed by reverse-
phase liquid chromatography using an Ascentis C18 5cm x 2.1mm with 3 µm particle 
size column. The chromatography and SRM methods were as described above for in vitro 
COX inhibition; transition for PG-EAs m/z = 413 378.  Product identities were 
confirmed by comparing the retention times and collision-induced dissociation spectra to 
standards.  
	  
Results 
 
NSAIDs of the arylpropionic acid class exhibit marked enantiospecificity for 
inhibition of AA oxygenation by COX enzymes.  The (S)-enantiomers of ibuprofen, 
flurbiprofen, and naproxen effectively inhibit COX-1 and COX-2, but the (R)-
enantiomers are either poor inhibitors or exhibit no observable inhibitory activity. As 
described in Chapter IV, the (S)-enantiomers of the arylpropionic acid class of NSAIDs 
are also potent inhibitors of COX-2-mediated 2-AG oxidation. To determine whether 
enantiospecificity is observed with the 2-AG as the substrate as it is for AA, we evaluated 
the ability of the (R)-enantiomers of ibuprofen, naproxen, and flurbiprofen to inhibit 2-
AG oxygenation by COX-2. As shown in Figure 1, (R)-enantiomers inhibit 2-AG 
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oxidation, albeit less potently than the (S)-enantiomers.  Importantly, (R)-ibuprofen, (R)-
naproxen, and (R)-flurbiprofen did not inhibit AA oxygenation by COX-2.  The 
experiments summarized in Figure 2 were performed at 50 µM substrate concentrations, 
so they were repeated at 5 µM substrate (the approximate Km for both substrates).  The 
IC50’s for inhibition of 2-AG oxygenation decreased ((R)-ibuprofen IC50 = 10 µM, (R)-
naproxen IC50 = 3.0 µM, (R)-flurbiprofen IC50 = 0.08 µM) but none of the three 
compounds inhibited AA oxygenation (data not shown).  Thus, the decrease in 
enantiospecificity for inhibition of 2-AG oxygenation compared to AA oxygenation 
observed at saturating substrate concentrations was maintained at substrate 
concentrations near the Km.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  
	  
Figure 1. Inhibition of COX-2-mediated AA and 2-AG oxygenation by (R)-profens. 
COX-2 was preincubated with 63 nM – 25 µM (R)-ibuprofen, (R)-naproxen or (R)-
flurbiprofen for 15 minutes followed by the addition of 50 µM AA () or 2-AG () for 
30 seconds. PG and PG-G production was measured by LC-MS/MS as described under 
Experimental Procedures.  
	  
These findings suggest that the (R)-enantiomers of arylpropionic acids bind in the 
COX-2 active site and inhibit the oxygenation of 2-AG. This was surprising given prior 
O OH
OH
OO OHO
F
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results suggesting that steric clashes with active site residues prevent binding of (R)-
arylpropionic acids (19). To ensure that (R)-profens inhibit 2-AG oxygenation by binding 
in the COX active site and not at the POX active site, we examined the ability of (R)-
naproxen to inhibit COX-2 POX activity. In these studies, POX activity was measured by 
monitoring the conversion of the POX hydroperoxide substrate PPHP to the 
corresponding alcohol, PPA, by HPLC.  As shown in Figure 2, no significant inhibition 
of POX activity was observed at concentrations of (R)-naproxen up to 500 µM, 
suggesting that the inhibitor does not bind at the POX active site. Similar results were 
obtained with (R)-flurbiprofen (data not shown).  
	  
Figure 2. Attempted inhibition of POX activity by (R)-naproxen. (R)-naproxen (100-
500 µM) was preincubated with mCOX-2 for 5 minutes at 37 °C prior to the addition of 
100 µM PPHP.  The reaction was quenched after 5 minutes by the addition of ethyl 
acetate with 0.5% acetic acid.  Conversion of PPHP to PPA was monitored by HPLC as 
described under Experimental Procedures.  	   	  
To determine the orientation of these substrate-selective inhibitors in the active 
site, attempts were made to crystallize complexes of each of the (R)-enantiomers with 
murine COX-2 utilizing recently described procedures. Diffraction-quality crystals were  
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Table	  I.	  Data	  collection	  and	  refinement	  statistics.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Values in parentheses correspond to the highest resolution shells. 
Rmerge = Σhkl Σj =1,N ⏐〈Ihkl〉 - Ihklj⏐/ Σhkl Σj =1,N ⏐Ihklj⏐where the outer sum (hkl) is taken over 
the unique reflections. 
Rwork = Σhkl ||Fo,hkl - k|Fc,hkl||/Σhkl|Fo,hkl|, where |Fo,hkl| and |Fc,hkl| are the observed and 
calculated structure factor amplitudes, respectively. 
Rfree is same as for Rwork for the set of reflections (5% of the total) omitted from the 
refinement process. 
NE-CAT, North Eastern Collaborative Access Team 
 
 
 
 
Data collection  
Space group I222 
Cell dimensions  
 a, b, c (Å)  
 α,β,γ (°) 
 
122.74, 133.03, 181.04 
90.00, 90.00, 90.00 
Resolution (Å) 2.4 (2.48-2.40) 
Rmerge (%) 11.7 (43.4) 
I/σI 15.7 (3.6) 
Completeness (%) 99.9 
Redundancy 5.7 (5.8) 
Refinement  
Resolution (Å) 2.4 
No. reflections 55701 
Rwork / Rfree 17.7 / 23.3 
No. of atoms  
      Protein 8946 
      Ligand  / Ions 332 / 2 
     Water 601 
B-factors   
      Protein 28.6 
      Ligand  / Ions 42.0 / 33.0 
      Water 31.7 
R.m.s. deviations  
      Bond lengths (Å) 0.008 
      Bond angles (°) 1.3 
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Figure 3. Crystal structure of (R)-naproxen bound in the active site of mCOX-2 at 
2.4 Å.  A. Difference electron density map (2Fo-Fc) contoured at 1σ shown in stereoview. 
B. Stereoview of the active site of the (R)-naproxen-COX-2 complex. Active site residues 
are shown as cyan sticks while the (R)-naproxen molecule is shown in lime sticks. The 
carboxylate moiety participates in hydrogen bonding interactions with Arg-120 and Tyr-
355. The (R)-a-methyl group is adjacent to Tyr-355.  
A 
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Figure 4. Comparison of the crystal structures of mCOX-2:(R)-naproxen and 
mCOX-2:(S)-naproxen. A. Overlay of the COX active site of the crystal structures of 
(R)-naproxen (inhibitor is shown in green, protein in cyan) and (S)-naproxen (purple) 
bound to mCOX-2. B. Crystal structure of (R)-naproxen (green) bound to mCOX-2 
(cyan). Hydrogren bonds between the carboxylate of the inhibitor and constriction site 
residues Arg-120 and Tyr-355 are shown in black lines with the distance (in angstroms) 
labeled. C.(S)-naproxen in the active site of mCOX-2. The inhibitor is shown in purple 
sticks and protein active site residues are shown in cyan. Black lines represent hydrogen 
bonds. 
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obtained with (R)-naproxen complexed to COX-2.  The electron density map and a stereo 
drawing of the bound inhibitor in the active site are shown in Figure 3A. The carboxylate 
of the inhibitor is located near the mouth of the active site coordinated to Arg-120 and the 
naphthyl ring projects up into the center of the active site. This is typical of the 
orientation of arylpropionic acids in the COX active site as been reported for (S)-
ibuprofen complexed to COX-1, (S)-naproxen complexed to COX-2, and (S)-flurbiprofen 
complexed to COX-1 or COX-2 (13,20-22). Previous reports based on site-directed 
mutagenesis and structure-activity relations have suggested that the α-methyl groups of 
the (R)-arylpropionic acids clash with Tyr-355 at the mouth of the active site to prevent 
stable binding (19). However, as illustrated in Figure 3B, the α-methyl group of (R)-
naproxen binds adjacent to Tyr-355. 
A comparison of the binding of (R)-naproxen to (S)-naproxen in the COX-2 active 
site is shown in Figure 4. The 1.7 Å mCOX-2:(S)-naproxen crystal structure is described 
in detail in Chapter III. The general binding modes of the two enantiomers are similar, 
although the chirality of the two α-methyl groups is reversed. The two naphthyl rings are 
nearly superimposed; however the naphthyl ring of (R)-naproxen appears to be shifted 
somewhat away from the side of the active site adjacent to the D-helix relative to the 
naphthyl ring of (S)-naproxen. The RMSD for the COX-2 active site residues of the two 
crystal structures is 0.18 Å, suggesting that the active site has slightly rearranged to 
accommodate the (R)-methyl group. The biggest difference in protein structure between 
the two complexes is the shift in the position of Tyr-355, which increases the hydrogen 
bond distance between the donor and acceptor to 3.05 Å in the (R)-naproxen:mCOX-2 
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structure compared to a distance of 2.44 Å for (S)-naproxen. This increase in hydrogen-
bonding distance may reduce the binding energy of the (R)-naproxen-COX-2 complex. 
(R)-Flurbiprofen exhibits analgesic activity in humans and inhibits neuropathic 
pain in rodents (6,23). It is not converted to (S)-flurbiprofen in vivo and does not display 
gastrointestinal toxicity (24). Further, (R)-flurbiprofen has been reported to elevate AEA 
levels in the dorsal horn of rats surgically treated to induce nerve injury (6).  The mode of 
action of (R)-flurbiprofen responsible for analgesia and AEA elevation is currently 
unknown, although it is a weak inhibitor of fatty acid amide hydrolase (IC50 = 1 mM in 
vitro) (6). Another possible explanation for the analgesic activity of (R)-flurbiprofen is 
that it inhibits the COX-2-selective metabolism of endocannabinoids. Support for this 
hypothesis comes from experiments conducted by Daniel Hermanson in our laboratory.  
He explored whether substrate-selective inhibition can be detected in intact cells with 
physiological levels of 2-AG and AEA using primary DRGs. Preliminary results 
indicated that increasing concentrations of (R)-flurbiprofen inhibited the synthesis of all 
three classes of eicosanoids, but the inhibition of the endocannabinoid-derived 
eicosanoids, PG-Gs and PG-EAs occurred at much lower concentrations than the 
inhibition of PGs (Figure 5). It is noteworthy that the stimulation of DRGs results in the 
generation of PG-EAs. This is the first time that these oxygenated metabolites of AEA 
have been detected in intact cells stimulated to release endogenous COX-2 substrates. 
The identity of the PG-EAs was verified by collision-induced dissociation and mass 
spectrometry of the fragments. It is also noteworthy that the	  concentration-dependences 
for inhibition of 2-AG oxygenation and AEA oxygenation are similar.	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Figure 5. Inhibition of endocannabinoid metabolism in DRGs.  DRGs were treated 
with varying concentrations of R-flurbiprofen for one hour prior to the addition of 
ionomycin to induce substrate release.  The culture medium was harvested after three 
hours and extracted with ethyl acetate containing 1% acetic acid and deuterated internal 
standards. The amount of product formation was measured by LC/MS-MS and 
quantitated by determining the ratio of the peak area of the eicosainoid species to that of 
the corresponding internal standard. (Experiment designed and performed by D. 
Hermanson). 	  	  
Discussion 
 
 The results presented here illustrate that (R)-enantiomers of arylpropionate 
inhibitors, which are considered inactive as COX inhibitors because of their inability to 
inhibit AA oxygenation, actually bind to the enzyme and inhibit endocannabinoid 
oxygenation. We hypothesize that binding of a single molecule of inhibitor in one 
monomer of the COX homodimer causes a conformational change in the partner 
monomer that is sufficient to prevent the productive binding of 2-AG, but not AA. The 
ability of (R)-arylpropionates to inhibit of endocannabinoid oxygenation under conditions 
where there is no observable inhibition of AA oxygenation is a dramatic illustration of 
substrate-selective inhibition. Further, the finding that (R)-arylpropionates inhibit COX-
2-mediated endocannabinoid metabolism raises the	   possibility that additional small	  
molecules that have been classified as ineffective against COX-2 as measured by 
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inhibition of PG production may be able to effectively bind COX-2 and prevent the 
formation PG-Gs and PG-EAs.	  
Previous studies suggested that (R)-arylpropionates could not effectively bind in 
the COX active site because of unfavorable steric interactions between Tyr-355 and the 
a-methyl group in the (R)-conformation (19). However, crystallographic analysis of (R)-
naproxen in complex with mCOX-2 indicates that the binding site of (R)-arylpropionates 
is the COX-2 active site. Co-crystallization of mCOX-2 with (R)-ibuprofen and (R)-
flurbiprofen will be important to confirm the binding site of (R)-arylpropionates. While 
(R)- and (S)- naproxen appear to occupy similar conformations within the COX-2 active 
site, the differential stereochemistry may lead to different molecular determinants for 
binding. Therefore, mutagenesis studies will be required to identify the binding 
determinants of (R)-arylpropionates within the COX-2 active site with particular focus on 
the amino acid residues involved in substrate-selective inhibition. This information will 
be useful in the design of (R)-arylpropionate derivatives with increased potency and/or 
selectivity against COX-2-mediated 2-AG oxygenation.  
These findings provide important new insights into the mechanism of action of 
NSAIDs and uncover a potential mechanism for the analgesic activity of (R)-
fluribiprofen. The ability of (R)-fluribiprofen to selectively inhibit AEA and 2-AG 
oxygenation in DRGs correlates to its ability to elevate AEA levels at sites of 
neuroinflammation in the spinal cord (6). Although fatty acid amide hydrolase and 
monoacylglycerol lipase are responsible for the basal turnover of endocannabinoids in 
non-inflammed tissue, induction of inflammation in the peripheral or central nervous 
system by nerve injury results in high levels of COX-2 in the inflamed tissue, which may 
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contribute to depletion of AEA and 2-AG. Blockage of this depletion by the 
endocannabinoid-selective inhibition of COX-2 by (R)-flurbiprofen would spare 
endocannabinoid levels and induce analgesia. Consistent with this mechanism, the 
analgesic effect of (R)-fluribiprofen is prevented by CB1 receptor antagonists despite the 
fact that (R)-fluribiprofen does not activate the CB1 receptor (6). This highlights the 
importance of maintenance of endocannabinoid tone in the analgesic action of (R)-
fluribiprofen. 	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CHAPTER VI 
 
SUMMARY 
 
 Naproxen has been marketed for the treatment of pain and inflammation for over 
thirty years. The inhibitor was developed prior to the isolation and purification of COX-1 
and long before the discovery of COX-2. Detailed studies of the molecular determinants 
of naproxen binding to COX had not been performed prior to the initiation of my 
dissertation project. Naproxen exhibits significant gastrointestinal toxicity but its 
cardiovascular toxicity appears lower than other drugs in its class. Recently, naproxen 
was reported to inhibit tumor growth in rodent models of urinary and colon cancers (1). 
The elucidation of critical interactions between naproxen and COX can be used in the 
design of more potent or selective naproxen analogs, which may be useful in dissecting 
the importance of isoform selectivity in cardiovascular toxicity or in the generation of 
gastrointestinal-sparing chemopreventive agents. 
 Kinetic studies indicate that naproxen interacts in a slightly different manner with 
COX-1 compared to COX-2. While there appears to be a time-dependent component to 
the inhibition of both COX-1 and COX-2, COX-1 is considerably more sensitive to 
inhibition by naproxen in the absence of a preincubation before the addition of substrate. 
The hypothesis that naproxen binds differently to COX-1 and COX-2 is supported by 
previous findings that mutations of COX-2 active site residues to the corresponding 
amino acid in COX-1 eliminate inhibition by naproxen despite the fact that naproxen is a 
non-selective inhibitor. The differential binding interactions between naproxen and the 
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active site of COX-2 and COX-1 could potentially be exploited in the development in 
selective naproxen analogs. However, our structure-activity studies show that each of the 
major functional groups of naproxen is required for inhibitory activity, suggesting that 
generation of active naproxen derivatives may be difficult. Changes in size and/or 
stereochemistry of either the α-methyl group or the p-methoxy group were not tolerated, 
and esterification of the carboxylic acid rendered naproxen inactive against both COX 
isoforms. Nevertheless, improved COX-2 selectivity was achieved by substitution of S or 
CH2 for the O atom of the p-methoxy group. In addition, our examination of the 
structure-activity relationship for naproxen led to the development of several close 
structural analogs of naproxen that do not inhibit the oxygenation of AA by COX-1 or 
COX-2 (e.g. α-ethyl naproxen and α,α-dimethyl naproxen); these compounds may be 
useful in the examination of the COX-independent effects of naproxen.  
 We utilized mutagenesis studies and x-ray crystallography to determine the 
binding mode of naproxen within the active site of COX-2. In addition to being the first 
structure to be solved by the Marnett laboratory the 1.7 Å mCOX-2:naproxen crystal 
structure is the highest resolution COX structure published and one of the highest 
reported for a membrane protein. Our successful development of an X-ray 
crystallography program will be useful in a variety of ongoing projects in our laboratory 
including efforts to generate novel COX-2 imaging agents and selective inhibitors of 
COX-2-mediated endocannabinoid metabolism. The high resolution of the mCOX-
2:naproxen structure allowed us to clearly define the conformation of naproxen and 
COX-2 active site residues and definitively identify solvent and detergent molecules. 
Although a critical interaction between naproxen and Trp-387 was not predicted by the 
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co-crystal structure, mutation of this residue to phenylalanine dramatically reduced the 
potency of naproxen but had no major effects on three other non-selective NSAIDs. 
Therefore, the interaction with Trp-387 appears to be a binding determinant that is unique 
to naproxen among NSAIDs. Although, the conformation of the p-methylthio-naproxen 
analog within the COX-2 active site is nearly identical to that of naproxen, the analog 
shows improved COX-2 selectivity and is not affected by the Trp-387 to phenylalanine 
mutation. These findings reinforce the concept that individual NSAIDs utilize a unique 
set of interactions to bind and inhibit the COX enzymes as well as highlight the 
importance of using crystallographic analyses in combination with mutagenesis and 
structure-activity studies to obtain a more complete understanding of inhibitor binding.  
 In addition to evaluating the molecular basis for inhibition of AA metabolism, our 
laboratory has a growing interest in elucidating the mechanism of inhibition of COX-2 
mediated oxygenation of the endocannabinoids, 2-AG and AEA, by NSAIDs. My 
research was focused on investigating the molecular determinants of  “substrate-
selective” inhibition as a follow-up to studies that showed two relatively weak, 
competitive inhibitors of AA metabolism, ibuprofen and mefenamic acid, were potent, 
non-competitive inhibitors of 2-AG oxygenation by COX-2. I was able to expand upon 
these findings, and show that reversible COX inhibitors, regardless of structure or 
isoform selectivity, are significantly more potent inhibitors of 2-AG oxygenation than 
AA oxygenation. I also demonstrated that slow, tight-binders inhibit AA and 2-AG 
metabolism by COX-2 with comparable IC50 values.  
These findings can be explained in light the recent discovery that COX monomers 
do not act independently of one another but rather exhibit cooperativity within the COX 
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homodimer. It appears that binding of a rapidly reversible inhibitor in one active site 
causes a conformational change in the partner monomer that prevents the oxygenation of 
2-AG but not AA. A second molecule of inhibitor must bind in the other monomer of the 
COX homodimer to block AA oxygenation. In contrast, if given an appropriate amount 
of time, binding of a molecule of a slow, tight-binding inhibitor in a single monomer of 
the COX-2 homodimer is sufficient to inhibit the metabolism of both AA and 2-AG.  
This hypothesis is consistent with previous studies that revealed that the stoichiometry of 
maximal inhibition by the slow, tight -binders, flurbiprofen and indomethacin, is one 
molecule of inhibitor per COX homodimer (2).  Our laboratory and others are attempting 
to identify the amino acid determinants of substrate-selective COX inhibition as well as 
visualize putative conformational changes, both in the active site and at the dimer 
interface.  
Regulating endocannabinoid levels may have important therapeutic benefits as 
these compounds have been shown to be mediators of analgesia and inflammation. The 
inhibition of 2-AG oxygenation may be partially responsible for the beneficial effects of 
NSAIDs in vivo. However, inhibition of traditional prostaglandin biosynthesis by 
NSAIDs is associated with gastrointestinal and cardiovascular toxicity and so, I sought to 
identify a truly selective inhibitor of COX-2 that could raise endocannabinoid levels 
without affecting AA. I was able to illustrate that (R)-enantiomers of the arylpropionate 
family of NSAIDs, which were previously thought to be inactive against COX enzymes, 
are effective inhibitors of 2-AG oxygenation by COX-2. Consistent with previous 
studies, virtually no inhibition of COX-2 mediated AA metabolism under identical 
conditions was observed. In agreement with these findings, this laboratory has observed 
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selective inhibition of PG-G and PG-EA formation by (R)-flurbiprofen in DRGs and 
macrophages. My crystallographic studies demonstrated that (R)-naproxen binds in the 
COX-2 active site, which contradicts earlier speculation that (R)-arylpropionates can not 
be accommodated in the COX active site because of unfavorable interactions between the 
α-methyl group and the constriction site residue, Tyr-355. The presence of (R)-naproxen 
only in the COX active site indicates that inhibition of 2-AG oxygenation does not result 
from binding in a separate, allosteric site. 
(R)-Arylpropionates represent the first examples of compounds that exclusively 
inhibit COX-2 mediated endocannabinoid oxygenation, albeit with moderate potency.  
Currently, this laboratory is attempting to generate (R)-arylpropionate derivatives with 
increased potency against 2-AG and AEA metabolism, as these would be useful probes in 
the examination of the physiological roles of PG-Gs or PG-EAs. Furthermore, 
compounds that act to raise endocannabinoid levels may have therapeutic potential in a 
variety of disease states, and therefore experiments are being conducted to confirm the 
hypothesis that selective inhibition of endocannabinoid oxygenation by COX-2 will 
effectively raise the levels of 2-AG and AEA, but not AA, in vivo. At present, the major 
focus of pharmacological endocannabinoid modulation has been on developing inhibitors 
of hydrolyzing enzymes (e.g. FAAH and MAGL), While these enzymes play a major role 
in the regulation of AEA and 2-AG, they also appear to act on additional substrates so 
that the pharmacological effects of their inhibitors may be broader than those mediated 
by endocannabinoids alone.  
The use of COX inhibitors in the treatment of pain and inflammation dates back 
over three thousand years, and investigators in the COX field are still working to 
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understand their precise mechanism of action. The research described herein resulted in a 
more complete understanding of the molecular basis for the action of one of the oldest 
and most widely used NSAIDs, naproxen. In addition, I have generated support for the 
hypothesis that the action of NSAIDs in vivo is not exclusively dependent on inhibition of 
prostaglandin biosynthesis but is also related to modulation of the endocannabinoid 
system. In the future, the identification of a substrate-selective COX-2 inhibitor may 
serve as the foundation for the development of novel therapeutic agents in the treatment 
of pain and/or inflammation.  
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